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Abstract  
Effects of marine lipid fraction PCSO-524™ supplementation on biochemical and functional 
measures of muscle damage and soreness in untrained men 
INTRODUCTION:   Intensive or unaccustomed eccentric exercise is known to cause 
exercise-induced muscle damage (EIMD) commonly resulting in delayed onset muscle soreness 
(DOMS). EIMD/DOMS can result in decrements in endurance and resistance exercise 
performance. Although many treatments have been investigated for the prevention and alleviation 
of EIMD/DOMS, success has been limited. PCSO-524™ has been found to attenuate symptoms 
of inflammatory diseases such as arthritis and asthma, and thus may be a viable treatment for 
EIMD/DOMS and may attenuate related exercise performance decrements.  
PURPOSE:   The purpose of this study was to examine whether or not PCSO-524™ 
supplementation could attenuate loss of range of motion, force loss, swelling, perceived pain 
through algometry and biochemical markers of inflammation, intracellular muscle proteins and 
oxidative stress after eccentric muscle damage.  
METHODS:   Subjects were thirty-two healthy, untrained males aged 18–26 who had 
not participated in a resistance training program in the past sixty days and did not exercise for 
more than three times per week for 30 minutes each session. Subjects supplemented for four 
weeks with either PCSO-524™ (400 mg/day) or placebo, after which time participated in a 20-
minute downhill run (DHR) at -16% grade.  Functional measures of DOMS were measured by 
algometry, midline thigh girth, and maximal voluntary contraction, following supplementation and 
24, 48, 72 and 96 hours following eccentric exercise.  Biochemical indicators of muscle damage 
such as Creatine Kinase-MM, Myoglobin, Slow skeletal troponin I, Fatty Acid Binding Protein 3, 
Interleukin-6, Tumor Necrosis Factor Alpha, 8-hydroxy-2' -deoxyguanosine (8-OHdG), and 
Cardiac Troponin I was measured pre-supplementation, post-supplementation and following DHR 
at 0, 2, 24, 48, 72 and 96 hours.  
RESULTS:   PCSO-524™ attenuated maximal voluntary contraction force loss 
significantly at 96 hours (F = 8.140 p < .001).  PCSO-524™ attenuated loss of range of motion at 
96 hours compared to baseline (F = 8.236  p < .05) for the PCSO-524™ group but did not change 
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for the placebo group.  There was no significant change in muscle swelling from baseline as 
measured by thigh girth for either PCSO-524™ or placebo.  There was no significant change in 
perceived muscle soreness as measured by algometry for either PCSO-524™ or placebo.  There 
was significant attenuation of creatine kinase MM in the blood following EMD immediately (t = 
4.467, p < .001; 95% CI = 63.0 – 169.2), 2 (t = 5.076, p < .001; 95% CI = 76.1 – 178.6), 24 (t = 
12.829, p < .001; 95% CI = 562.5 – 775.6), 48 (t = 11.477, p < .001; 95% CI = 493.2 – 706.7), 72 
(t =9.118, p < .001; 95% CI = 359.8 – 567.5), and 96 hours (t = 11.935, p < .001; 95% CI = 574.4 
– 811.6).  Significant attenuation of myoglobin occurred 24 (t = 4.334, p < .001; 95% CI = 22.9 – 
63.7), 48 (t = 6.402, p < .001; 95% CI = 67.7 – 131.1), 72 (t = 5.340, p < .001; 95% CI = 119.0 – 
266.3), and 96 hours (t = 3.272, p < .01; 95% CI = 49.0 – 212.3) compared to placebo.  
Significant attenuation of skeletal muscle troponin I occurred in the PCSO-524™ group compared 
to placebo 2 (t = 2.562, p < .05; 95% CI = 0.9 – 8.0), 24 (t = 3.561, p < .01; 95% CI = 4.4 – 15.4), 
48 (t = 4.095, p < .001; 95% CI = 4.7 – 14.0), 72 (T = 3.222, p < .01; 95% CI = 2.5 – 11.2), and 96 
hours (T = 2.177, p < .05; 95% CI = 0.3 – 10.4) post EIMD.  No significant effect of 
supplementation status on fatty acid binding protein appearance in the blood (F = .418 p = .523) 
post EMID.  Significant attenuation of Interleukin-6 was observed 24 (t = 3.619, p < .01; 95% CI = 
3.7 – 13.3), 48 (t = 3.993, p < .001; 95% CI = 5.8 – 17.8), 72 (t = 3.621, p < .01; 95% CI = 5.0 – 
17.9), and 96 hours (t = 3.076, p < .01; 95% CI = 3.1 – 15.35) post EMID compared to placebo. A 
significant effect of time on TNF alpha concentration in the blood (F = 132.012 p < .001) was 
observed 24 (t = 4.633, p < .001; 95% CI = 11.1 – 28.5), 48 (t = 4.942, p < .001; 95% CI = 10.6 – 
25.7), 72 (t = 4.747, p < .001; 95% CI = 11.3 – 28.5), and 96 hours (t = 6.349, p < .001; 95% CI = 
16.8 – 32.8) post EIMD.  No significant effect of time on 8-OHdG concentration in the blood (F = 
1.018 p  .419) was observed in either the PCSO-524™ group or placebo after EIMD.  No 
significant effect of time was observed on cTn1 concentration in the blood (F = .420 p = .889) in 
either PCSO-524™ or placebo after EIMD. 
CONCLUSIONS:  Four weeks of PCSO-524™ supplementation does not improve swelling 
as determined by thigh girth; perceived pain by the use of algometry; appearance of Fatty Acid 
Binding Protein, 8-hydroxy-2' -deoxyguanosine (8-OHdG), and Cardiac Troponin I in the blood in 
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untrained males after downhill running compared to placebo. Four weeks of PCSO-524™ 
supplementation is effective at attenuating maximal voluntary contraction force loss; loss of range 
of motion; and reducing the appearance of creatine kinase-MM; skeletal muscle troponin I; 
interleukin-6; and Tumor Necrosis Factor- alpha in the blood in untrained males after downhill 
running. 
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Chapter 1: Introduction 
 
Exercise-induced muscle damage (EIMD) is an event that occurs after unaccustomed eccentric 
exercise and sustained metabolically demanding activities, resulting in a temporary rise in 
passive muscle tension, decrease in muscle force production (Ebbeling & Clarkson, 1989), 
increased perceptions of muscle soreness (Miles & Clarkson, 1994), localized swelling (Howell, 
Chleboun, & Conatser, 1993) (Howatson & Van Someren, 2008), decreased range of motion 
(Kazunori Nosaka & Clarkson, 1995) (McHugh et al., 1999) and greater concentrations of 
intramuscular proteins in blood (Howatson & Van Someren, 2008) (Stephan Sorichter et al., 
1997).  While the causes of muscle damage are unclear, literature points to mechanical damage, 
oxidative damage and a combination of both.   
  
Mechanical damage to the muscle results from the disruption of contractile filaments of muscle 
tissue especially following eccentric exercise (D. J. Newham, D. A. Jones, & P. M. Clarkson, 
1987).  Myofibril structural changes post-eccentric exercise are evidenced by broadening or total 
disruption of z-lines (Cheung, Hume, & Maxwell, 2003) (Garrett & Kirkendall, 2000), myofilament 
loss, reduced numbers of mitochondria, disturbed A-band filaments (J. Friden, Sjostrom, & 
Ekblom, 1981) (J Friden, Kjörell, & Thornell, 1984), and extracellular matrix disruption due to 
inflammation (Stauber, Clarkson, Fritz, & Evans, 1990). 
 
 While the exact mechanism of loss of force is unknown, it has been hypothesized that the cause 
may lie in the tendon attachments, elastic muscle elements or loss of function of the excitation 
contraction coupling (Warren et al., 1993).  Force loss is immediate, but temporary, with more 
intense bouts of exercise correlated to greater losses in magnitude requiring a longer duration 
until force production is restored to baseline levels (D. Newham, D. Jones, & P. Clarkson, 1987).  
Additionally, training status appears to play a role in the extent of muscle damage with untrained 
subjects experiencing a greater degree of EIMD/DOMS than trained individuals (Proske & 
Morgan, 2001).   
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Muscle damage results in increased swelling due to an influx of fluid into the muscle cell as 
evidenced by MRI (Shellock, Fukunaga, Mink, & Edgerton, 1991).  Swelling is most pronounced 6 
days post-muscle damaging exercise, and is thought to occur either due to connective tissue 
injury, increased capillary permeability, muscle cell protein degradation, or a combination of 
factors. (Mair et al., 1992) (Takahashi et al., 1994).  Swelling is thought to be responsible for the 
increase in the sensation of pain due to fluid influx into the damaged muscle and subsequent 
increase in pressure on nociceptors (Crenshaw, Thornell, & Friden, 1994). 
 
Muscle damage results in increased levels of intracellular proteins in the blood such as skeletal 
muscle troponin 1, fatty acid binding protein, myoglobin (Mb) and inflammatory mediators such as 
interleukin-6 (IL-6) and tumor necrosis factor (TNF-α).  It is thought that intracellular proteins 
diffuse out of the cell into the surrounding tissue and capillaries due to either sheer stress or free 
radical damage to the membrane following eccentric exercise (W. Evans & Cannon, 1991).  
These proteins attract macrophages and T-cells, which release inflammatory mediators that 
amplify the initial muscle injury through increased release of activation of phospholipases, 
proteases, and reactive oxygen species causing inflammation (MacIntyre, Reid, & McKenzie, 
1995) (P. Calder & Grimble, 2002).  These mediators, in addition to cytokines, such as IL-6, 
coordinate the immune response at the site of injury.  IL-6 is a pro-inflammatory cytokine involved 
in lipid peroxidation which degrades the cell membrane (Hinson, Williams, & Shacter, 1996).  
TNF-α is another important mediator of the inflammation process with elevated expression in 
injured muscle fibers (R. A. Collins & Grounds, 2001) and necessary for muscle repair (Y.-P. Li, 
2003). Treatment strategies have sought to minimize inflammation inhibiting the inflammatory 
pathways and immune cell activation by the use of NSAIDs and antioxidants such as fish oil (P. 
Calder & Grimble, 2002) .  NSAIDs inhibit inflammatory pathways, such as COX-2, while fish oil, 
which contains n-3 PUFAs such as eicosapentaeoic (EPA) and docosahexaenoic acid (DHA) 
inhibit lymphocyte proliferation and the inflammatory cascade (Dubois et al., 1998; Trebble et al., 
2003).  However inflammation may provide a vital role in muscle repair as performance is 
inhibited when the inflammatory process is impaired (Almekinders, 1999).  Free radicals can also 
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be generated from inflammatory cells responding to increases in markers of cellular damage such 
as TNF-α, Myoglobin (Mb) and creatine kinase (CK) released into the blood from ruptured cells.  
Inflammatory cells increase rates of tissue destruction and remodeling through the recruitment of 
macrophages through increased concentrations of cytokines and interleukins (Tiidus, 2008).   
 
Therapies seeking to minimize EIMD/DOMS have typically inhibited COX2 enzymes with the use 
of over the counter non-steroidal anti-inflammatory drugs (NSAIDs) such as Tylenol or Aleve.  
NSAIDs inhibit prostaglandin formation which are important mediators for the inflammatory 
response (Burian & Geisslinger, 2005).  Studies have found that NSAID supplementation post-
eccentric muscle exercise can improve contractile function and reduce circulating levels of 
inflammatory cells and intercellular muscle enzymes (Howatson & Van Someren, 2008; Mishra, 
Friden, Schmitz, & Lieber, 1995).  However, chronic NSAID use has been linked to gastric 
bleeding, fluid retention, hypertension and acute renal failure if taken too close to exercise 
(Boulter, Noakes, & Hew-Butler, 2011; Derry & Loke, 2000). 
 
While metabolism of the components in fish oil such as EPA and DHA are less inflammatory and 
used in the same metabolic pathway as NSAIDs, studies are inconclusive on whether fish oil 
supplementation on EIMD/DOMS treatment is effective (Macaluso et al., 2013).  For example, 
1.8g/day omega 3 supplementation proved effective in ameliorating delayed onset muscle 
soreness in untrained males after eccentric knee exercise (Bakhtiar Tartibian, Behzad Hajizadeh 
Maleki, & Asghar Abbasi, 2009).  However, it has been shown that n-3 PUFA supplementation at 
1.8g/day for 30 days was not effective in attenuating the acute phase inflammatory response or 
functional measures of muscle damage after 50 repetitions of elbow flexion exercise in 22 healthy 
male subjects (Lenn et al., 2002). 
 
In addition to the immune system, metabolic processes such as the electron transport chain 
within the mitochondria generate free radicals which damage the muscle sarcolemma 
phospholipids through lipid peroxidation, causing a loss of membrane integrity ultimately leading 
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to cell death (Davies, Quintanilha, Brooks, & Packer, 1982).  Lipid peroxidation can be quantified 
by using fatty acid binding protein which selectively binds to the products of lipid peroxidation and 
is involved in intracellular membrane transfer (B. A. McMahon & Murray, 2010) (Weisiger, 2002).  
It has been found that preventing free radical formation resulted in decreased sensations of 
muscle damage with the extent of cellular damage quantified using 8-Oxo-2'-deoxyguanosine (8-
OHdG) as a marker of DNA oxidative damage (A. R. Collins, Dusinská, Gedik, & Sĕtina, 1996) 
(Mastaloudis et al., 2004).  8-OHdG production results from the interaction between free radicals 
and DNA which may result in purine-pyrimidine base substitution mutations linked to inflammation 
(de Souza-Pinto et al., 2001).   
 
Treatment of oxidative damage can be minimized through consumption of food and supplements 
rich in antioxidants such as vitamin E, C and beta carotene (Powers, Ji, & Leeuwenburgh, 1999).  
These compounds react with the free radicals and neutralize them, thus preventing damage to 
the cell membrane (Machlin & Bendich, 1987).  Additionally, damaging reactions can be 
attenuated with consumption of foods rich in n-3 PUFAs such as eicosapentaenoic acid (EHA) 
and docosahexaenoic acid (DHA) due to their ability to be preferentially oxidized instead of the 
phospholipids that comprise the membrane (Thompson et al., 2001).  DHA is an n-3 PUFA that is 
a structural component of the phospholipid bilayer that can be synthesized from alpha-linolenic 
acid or obtained directly from fish oil.  DHA is a carboxylic acid with a 22-carbon chain and six cis 
double bonds with the first double bond located at the third carbon from the omega end (Guesnet 
& Alessandri, 2011).  Eicosapentaenoic acid (EPA) is an n-3 PUFA which acts as a precursor for 
prostaglandin-3, thromboxane-3, and leukotriene-5 groups (Schmitz & Ecker, 2008).  The number 
and placement of the double bonds in the EPA and DHA contribute to it’s anti-inflammatory 
properties compared to n-6 PUFAs (arachidonic acid) when oxidized by free radicals during lipid 
peroxidation (Mori et al., 2000). 
 
Supplementing with n-3 PUFAs, such as EPA and DHA, have been used to treat inflammation in 
patients with certain chronic inflammatory diseases such as arthritis and asthma (James & 
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Cleland, 1997; Mickleborough, Lindley, Ionescu, & Fly, 2006).  Cellular membrane incorporation 
of polyunsaturated fatty acids, particularly EPA and DHA, decrease release of pro-inflammatory 
mediators such as 2-series prostaglandins and 4–series leukotrienes (Eriksen, Sandvik, & 
Bruusgaard, 1996). 
 
Prostaglandins and leukotrienes are a subfamily of inflammatory mediators known as eicosanoids 
that are signaling molecules that mediate inflammation, fever and pain and derived from either n-
3 or n-6 PUFAs from the phospholipids of the cell membrane.  While products of both n-3 or n-6 
PUFAs are generally considered inflammatory, n-3 PUFAs are less inflammatory than n-6 PUFAs 
(De Meester, Watson, & Zibadi, 2013).  Prostaglandin synthesis proceeds along the 
cyclooxygenase-1, and cyclooxygenase-2 pathways while leukotriene biosynthesis proceeds 
along the 5, 12, and 15-lipoxygenase pathways in response to cytokines, growth factors and 
other inflammatory stimuli (Ballou, Botting, Goorha, Zhang, & Vane, 2000). Prostaglandins 
contribute to pain by directly activating pain receptors by increasing levels of cyclic AMP and 
enhancing nociceptor sensitization (Rueff & Dray, 1993).  It has been shown that diets high in n-3 
PUFAs reduce the effect of inflammatory diseases such as asthma and arthritis by affecting 
eicosanoid production (Harizi, Corcuff, & Gualde, 2008) (Kremer et al., 1985) (P. Calder & 
Grimble, 2002).  
 
Chemical analysis has elucidated that the New Zealand green-lipped mussel (NZGLM) known as 
Perna canaliculus, contains EPA and DHA, 91 different polyunsaturated and furan fatty acids 
(Wolyniak, Brenna, Murphy, & Sinclair, 2005).  The EPA and DHA composition is approximately 
13% EPA, 21% DHA, 30% cholesterol and contains up to 91 polyunsaturated fatty acids including 
5,9,12,15-octodecatretraenoic acid, 5,9,12,16-nondecatertraenoic acid, 7,11,14,17-
eicosatetraenoic acid, 5,9,12,15,18-heneicsapententaenoic acid, oleic acid, stearic acid, 
palmitoleic acid, palmitic acid and myristic acid (Wolyniak, et al., 2005).  PCSO-524™ 
(Lyprinol/Omega XL) is a supplement manufactured from the New Zealand Green Lipped Mussel 
that has been shown to reduce airway inflammation and bronchoconstriction in asthmatics, 
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attenuate colon inflammation in irritable bowel syndrome, decrease joint inflammation in 
rheumatoid arthritis patients, and reduce ADHD symptoms in children (Kean et al., 2013; 
Mickleborough, Vaughn, Shei, Davis, & Wilhite, 2013; Tenikoff, Murphy, Le, Howe, & Howarth, 
2005; Zawadzki, Janosch, & Szechinski, 2013a). 
 
Additionally, PCSO-524™ contains furan fatty acids which have been shown to possess greater 
anti-inflammatory properties than EPA and DHA alone by quenching the lipid peroxidation 
processes in the cell by the free radical scavenging properties of the furan ring in 
Dehalococcoides bacterial strains (Teixeira, Cox, & Egmond, 2013; White et al., 2005).  Free 
radical scavengers reduce pro-inflammatory lipid peroxidation products such as leukotriene B4 
(LTB4) in human monocytes and LTB4 and eicosanoids such as 5-Hydroxyeicosatetraenoic acid 
(5(S)-HETE) in human neutrophils, inhibit the COX-1 and COX-2 enzymes, prevent interleukin 
tumor necrosis factor and interferon synthesis.  (Wakimoto et al., 2011). Ingestion of PCSO-
524™ in osteoarthritic patients reduced perceptions of pain compared to fish oil (Zawadzki, 
Janosch, & Szechinski, 2013b).   
 
Additionally, PCSO-524™ has shown potent anti-inflammatory activity in rat paw edema assays 
at a concentration lower than fish oil, which contained abundant EPA (M. Whitehouse, 2001).  
PCSO-524™ has been shown to be more effective than fish oil in reducing symptoms of 
experimentally induced inflammatory bowel disease (Tenikoff, et al., 2005).  This suggests that 
the anti-inflammatory effects of PCSO-524™ may not be solely due to the EPA and DHA content, 
since the n-3 PUFA content of PCSO-524™ compared to fish oil is significantly lower (Tenikoff, 
Murphy, Le, Howe, & Howarth, 2005).  Since none of the fatty acids are unique to PCSO-524™, it 
is possible that that additional ingredients such as the 91 polyunsaturated fatty acids and furan 
components act together with n-3 PUFAs to attenuate the inflammatory response (Wakimoto, et 
al., 2011).  
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Important to this study, runners supplemented with PCSO-524™, experienced less DOMS 
following a 30-kilometer run than placebo (Baum, Telford, & Cunningham, 2013). However, 
Pumpa et al. (2011) demonstrated that 8 weeks of supplementation with 200 mg/day of PCSO-
524™ did not affect performance measures (Visual analogue scale, algometry, and force 
production) and biochemical markers (IL-6 IL-10, TNF-alpha, C reactive protein, myoglobin, and 
creatine kinase) compared to placebo (Pumpa, Fallon, Bensoussan, & Papalia, 2011).   
Therefore, the data are equivocal as to whether PCSO-524™ can attenuate the functional and 
biochemical markers of muscle damage. 
Statement of the Problem 
It has been shown that EPA and DHA supplementation attenuate acute tissue inflammation and 
minimize DOMS.  DOMS and inflammation are two of the symptoms of EIMD which when 
exacerbated through chronic training may result in greater tissue damage and decreased strength 
gains.  PCSO-524™ is a marine extract from the New Zealand Green Lipped Muscle, and has 
been shown effective in attenuating inflammation in chronic inflammatory diseases such as 
asthma, rheumatoid arthritis, and irritable bowel syndrome.  PCSO 524’s™ effectiveness in 
reducing inflammation may be due not only to its EPA and DHA content, but also its furan fatty 
acids and up to 91 different lipids which are thought to integrate into the membrane and provide a 
less inflammatory substrate and absorb reactive oxygen species thereby minimizing tissue 
damage.  To date, there has been no research investigating the ability of PCSO-524™ 
(Lyprinol®/Omega XL®) to attenuate the functional and biochemical measures of EIMD/DOMS in 
untrained males after a continuous bout of eccentric aerobic exercise. 
 
Hypotheses 
Hypothesis 1: The percent change in force production from baseline for subjects that consumed 
PCSO-524™ will be higher compared to those that consumed placebo. 
 
Hypothesis 2: The percent change in quadriceps range of motion from baseline for subjects that 
consumed PCSO-524™ will be higher, compared to placebo. 
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Hypothesis 3: The percent change in size of the midline of the quadriceps will be less in subjects 
that supplemented with PCSO-524™ than placebo. 
 
Hypothesis 4: The percent change in the perception of pain at the quadriceps from baseline 
measured by algometry in subjects that supplemented with PCSO-524™ will be less than  
compared to placebo. 
 
Hypothesis 5: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of creatine kinase in the blood post eccentric muscle damage compared to placebo. 
 
Hypothesis 6: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of myoglobin in the blood post eccentric muscle damage compared to placebo. 
 
Hypothesis 7: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of skeletal muscle troponin I in the blood post- eccentric muscle damage compared 
to placebo. 
 
Hypothesis 8: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of fatty acid binding protein in the blood post- eccentric muscle damage compared to 
placebo. 
 
Hypothesis 9: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of interleukin-6 in the blood post eccentric muscle damage compared to placebo. 
 
Hypothesis 10: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of TNF alpha in the blood post eccentric muscle damage compared to placebo. 
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Hypothesis 11: Supplementing untrained men with PCSO-524™ for 4 weeks will lessen the 
appearance of cardiac muscle troponin I in the blood post- eccentric muscle damage compared to 
placebo. 
 
Purpose of the Study 
The purpose of this study was to evaluate whether chronic PCSO-524™ supplementation in 
untrained males attenuates exercise induced muscle damage following eccentric muscle 
exercise; specifically reduction in range of motion, perceived muscle soreness, cytokines, muscle 
proteins, and inflammatory mediators. 
Delimitations 
Untrained males were recruited from the Indiana University classifieds and tested in a laboratory 
setting with environmental conditions carefully controlled.  Muscle damaging exercise was 
performed in a laboratory setting on a treadmill at a predetermined speed.  Subjects were asked 
to refrain from consuming fish oil, NSAIDS, or marine related products during the course of the 
study.  Additionally, subjects were requested not to consume alcohol or caffeine for at least 24 
hours prior to lab testing.  Additionally subjects maintained their normal diet and were asked not 
to exercise more than 30 minutes a day, three days a week while refraining from performing any 
eccentric exercise.  Blood draws were performed at the same time during subsequent days. 
Limitations 
Since personal histories were self-reported, subjects could have misrepresented their background 
or exercise habits in order to gain access to the study.  Additionally, since supplementation was 
performed away from the lab and self reported, subjects might not have consumed the required 
number of capsules during the supplementation period.  Subject pain perception might have 
varied between visits and while spots were marked to ensure consistent measurement, some 
subjects repeatedly washed markers off which may have resulted in marks not being reapplied in 
exactly the same location on subsequent days.  For range of motion the goniometer relied on a 
correct point of view and alignment, even slight variations of the instrument may result in large 
deviations. 
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Assumptions 
Subjects did not change their diet or exercise habits throughout the study.  Subjects did not 
change their perception of pain throughout the study.  The treadmill protocol was a valid and 
sufficient method in inducing exercise induced muscle damage.  Subjects were motivated to 
complete the study and were rested and hydrated prior to their visit. Algometry tests were 
subjective and the amount of pain perception by each subject did not vary between lab visits.  
Blood draws were performed in such a way that no significant hemolysis occurred. 
Definition of terms 
8-OHdG:  8-Hydroxyguanosine is a nucleoside marker of oxidative stress.  Its appearance is 
thought to be the result of DNA damage as a result of free radical exposure (Wu, Chiou, Chang, 
& Wu, 2004). 
 
Akt/mTOR/S6K1: A signaling cascade which plays an important role both in cell survival (Gingras 
et al., 2007b). 
 
COX: Cyclooxygenase is an enzyme that creates prostanoids, including prostaglandins, 
prostacyclin and thromboxane.  These products contribute to pain and inflammation (Seibert et 
al., 1995). 
 
DAG: Diglycerol A Glyceride consisting of two fatty acid chains covalently bonded to a glycerol 
molecule through ester linkages. DAG is a second messenger signaling lipid, that is produced by 
the hydrolysis of the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme 
phospholipase C which results in inositol trisphosphate (IP3) (Hardie, 2003). 
 
NF-κB: A protein complex that controls the transcription of DNA. NF-κB is thought to be 
involved in cellular responses to stimuli such as stress, cytokines, and free radicals.  NF-κB 
regulates the immune response (Shih, Tsui, Caldwell, & Hoffmann, 2010). 
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p70s6k: a serine/threonine kinase that acts downstream of PIP3 and phosphoinositide-dependent 
kinase-1 in the PI3 kinase pathway and is activated by mTOR inducing protein synthesis at the 
ribosome.  Physical exercise has been shown to phosphorylate p70s6k which results in protein 
synthesis (Pearson et al., 1995). 
 
PCSO-524™:  A marine lipid extract from the New Zealand green-lipped mussel (Perna 
canaliculus).  The extract contains 30 polyunsaturated fatty acids including the essential n-3 
PUFAs such as DHA and EPA, furan fatty acids and up to 91 polar lipids (Wakimoto, et al., 2011).  
 
PIP2: Phosphatidylinositol 4,5-bisphosphate is a minor phospholipid component of cell 
membranes.  PIP2 is enriched at the plasma membrane where it is a substrate for a number of 
important signaling proteins in the IP3/DAG pathway (Czech, 2000). 
 
PIP3:  Is a phospholipid that resides on the plasma membrane that activates downstream 
signaling components, such as protein kinase AKT, which activates downstream anabolic 
signaling pathways required for cell growth and survival (Czech, 2000). 
 
PLA2: A class of enzymes that recognize and catalytically hydrolyze the sn-2 acyl bond of 
phospholipids releasing arachidonic acid that undergoes modification into active compounds by 
cyclooxygenase enzymes resulting in formation of eicosanoids that include prostaglandins and 
leukotrienes that can act as pro and anti-inflammatory mediators (Balsinde, Balboa, Insel, & 
Dennis, 1999).  
 
PUFA: Fatty acids have 2 or more cis double bonds that are separated from each other by a 
single methylene bridge.  Fatty acid notation can be is X:Y where X is the length of the carbon 
chain and Y is the number of methylene bridges in the compound (C. M. Williams & Burdge, 
2006).  
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ROM: Range of Motion is the angular distance that a limb may normally travel while attached to 
another (H. M. Clarkson, 2000).  
 
ROS: Chemically reactive molecules containing oxygen which are formed as the byproduct of 
metabolism and play important roles in cell signaling and homeostasis and increase dramatically 
during times of cellular stress which can cause damage to cellular structures (Kane et al., 1993). 
Chapter 2: Literature review 
 
PCSO-524™  
The green-lipped mussel is native to New Zealand and an integral part of the diets of coastal 
indigenous tribes and is thought to contribute to a lower incidence of arthritis compared to inland 
tribes due to its anti-inflammatory properties.  Recent attempts to purify the compound to create a 
supplement for arthritis sufferers proved difficult due to the instability of the active components 
resulting in products with no anti-inflammatory capacity (Galliard, 1970).  Purification was finally 
achieved through the use of supercritical fluid extraction and the resulting compound is known as 
PCSO-524™.  PCSO-524™ is consumed in capsule form under the tradename Lyprinol® and 
Omega XL® with each capsule containing 50 mg PSCO-524™ lipid extract, 100 mg olive oil and 
0.225 mg vitamin E (d-α-tocopherol).   PCSO-524™ contains a multitude of lipid classes 
including triglycerides, sterol esters, polar lipids, free fatty acids, and sterols.  Ninety-one fatty 
acid components have been identified in PSCO-524™ including, palmitic acid, 5,9,12,16-
nondecatertraenoic acid, 5,9,12,15,18-heneicsapententaenoic acid, myristic acid, 5,9,12,15-
octodecatretraenoic acid, palmitoleic acid, stearic acid, oleic acid and 7,11,14,17-eicosatetraenoic 
acid.  Omega fatty acids were the most abundant unsaturated fatty acids in PSCO-524™ with 
140 mg/mL eicosapentaenoic acid (EPA, 20:5) and 87 mg/mL docosahexaenoic acid (DHA, 22:6) 
present in the purified extract (Murphy, Mooney, Mann, Nichols, & Sinclair, 2002; Wolyniak, et al., 
2005).   
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PCSO-524™ has been investigated with positive effects in both acute and chronic inflammatory 
diseases, such as asthma, osteoarthritis in rats, inflammatory bowel disease models in mice and 
acute inflammation such as muscle soreness after a 30 kilometer run in humans (Baum, et al., 
2013; Lello, Liang, Robinson, Leutenegger, & Wheat, 2012; Tenikoff, et al., 2005; Zawadzki, 
Janosch, & Szechinski, 2013c).  
 
Lello at al (2012) investigated PCSO-524™ supplementation in asthmatic children aged 6 to 13 
years old. 71 children participated in the 16-week, double blind placebo-controlled study and 
received either 2 capsules daily Lyprinol® or placebo and were maintained on an as-needed 
inhaled corticosteroid. The study found that PCSO-524™ supplementation decreased the 
percentage of children reporting trouble with their asthma symptoms at three months of treatment 
(97% vs. 76% p = 0.057). PCSO-524™ attenuated mild and moderate asthma exacerbations.  
The study found that PCSO-524™ has a positive effect for asthma sufferers and should be 
considered a nutritional supplement for children with moderate asthma and possibly a 
supplement to conventional asthma therapy. 
 
Zawadzki at al. (2013) demonstrated that PCSO-524™ supplementation attenuates pain to a 
greater extent compared to fish oil supplementation alone.  47 patients completed the 
randomized blind study with 22 patients supplementing with 1200 mg/day (4 capsules) PCSO-
524™ and 25 subjects supplementing with fish oil (4 capsules; 150 mg/capsule; total n-3 PUFA 
18% EPA and 12% DHA).  Patients supplemented with PCSO-524™ showed a statistically 
significant improvement compared with patients who took fish oil. PCSO-524™ supplementation 
resulted in lower pain scores within four weeks, improvement in health and disease, and 
increased blood cell count.  Patients that supplemented with fish oil showed significantly less 
improvement and a greater level of physical discomfort during the study.  
 
Investigating the potential of PCSO-524™ supplementation on DOMS symptoms, Baum et al. 
(2013) found after a 30 kilometer run by 32 nonprofessional distance runners, compared to no 
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changes in the control group while runners supplemented with PCSO-524™ had significant 
attenuation of muscle soreness following their post-treatment run compared to the pre-treatment 
run. Median baseline pain scores for the control group did not differ from post-treatment pain 
scores in the PCSO-524™ group.  Runners that trained under 3 times a week experienced the 
greatest benefit in attenuated DOMS perception suggesting that PCSO-524™ supplementation 
may be effected by training status and suited for untrained rather than trained athletes due to lack 
of conditioning. 
 
Additionally, other studies found that subject-training status was important for the study outcome 
as evidenced by Pumpa et al. (2013) who showed PCSO-524™ was ineffective at attenuating the 
symptoms of DOMS effective in 20 well-trained male subjects. Each group of 10 subjects 
consumed an olive oil capsule (placebo) or 200 mg of PCSO-524™ daily for eight weeks. After 
the supplementation period, muscle damage was induced with each subject performing 5 bouts of 
8 minutes running downhill at a −10% gradient with 2 minutes level walking between bouts at 
80% maximal heart rate.  The results suggest that PCSO-524™ supplementation at 200 mg/day 
was ineffective at attenuating the symptoms of DOMS with no significant differences between 
groups on functional measures such as perception of pain, algometry and biochemical markers 
such as Interleukin-1, Interleukin-6, Interleukin-10, C-reactive protein, creatine kinase, tumor 
necrosis factor-α, and myoglobin spaced 4, 24, 48, 72 and 96 hours after muscle damage 
(Pumpa, et al., 2011). 
 
PCSO-524™’s effectiveness may have beneficial effects on muscle damage and recovery 
processes by minimizing the inflammatory response and DOMS that occurs following EIMD in 
untrained individuals. There are numerous histological changes that occur inside the muscle cell 
after it has been damaged, including toxic intracellular proteins which leak out of the cell into the 
microenvironment which attract macrophages which release reactive oxygen species causing 
further damage to both injured and healthy muscle cells.  Additionally there is an increase in 
cytosolic calcium due to increased sarcoplasmic reticulum permeability resulting in 
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Phospholipase A2 activation which cleaves unsaturated membrane phospholipids to initiate the 
arachidonic acid cascade which is an eicosanoid precursor including four-series leukotrienes 
(LT4) and two-series prostaglandins (PGE2) catalyzed by cyclooxygenase and 5-lipoxygenase.  
The arachidonic acid cascade culminates in membrane damage if lipid peroxidation is excessive.  
Additionally elevated levels of calcium cause rapid damage of force generating myofilaments 
(Duncan, 1988).  
 
PCSO-524™’s anti-inflammatory ability for inhibition of both cyclooxygenase-2 and 5-
lipoxygenase inhibiting leukotriene B4 (LTB4) and prostaglandin production has been 
demonstrated in both human polymorphonucleocytes and neutrophils (M. W. Whitehouse et al., 
1997).  Additionally PCSO-524™ contains furan fatty acids that scavenge reactive oxygen 
species produced from activated neutrophil and cellular metabolic processes and have been 
shown to have antioxidant effects (Ishii, Okajima, Koyamatsu, Okada, & Watanabe, 1988). It is 
hypothesized that furan fatty acids have a tetraalkyl-substituted furan ring, which is susceptible to 
oxidation, and the subsequent ring opening generates dioxoene, which is highly reactive and 
further converted to other compounds.  Dioxenes are extremely reactive, causing total inhibition 
of products of the arachidonic acid pathway at concentrations as low as 20 μM (Graff, 
Gellerman, Sand, & Schlenk, 1984).   These naturally but rarely detected fatty acids show a 
potent radical-scavenging ability and are essential constituents of plants and algae and have 
recently started to become appreciated as a key link between the cardio protective effects of a 
diet high in EPA and DHA (Spiteller, 2005).  For example, PCSO-524™ had greater anti-
inflammatory activity in a rat model of adjuvant-induced arthritis than the same dose of EPA and 
DHA alone. (Wakimoto, et al., 2011).   
Process of Muscle Damage  
Muscle damage, which can occur as a result of eccentric muscle action, is postulated to follow 
five phases: the initiating event, early structural changes, necrosis and degeneration, 
regeneration, and protection from further insults.  Muscle damage has been shown to be localized 
and only affect a small percentage of muscle fibers in skeletal muscle (H Kuipers, Drukker, 
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Frederik, Geurten, & Kranenburg, 1983).  Initial events in muscle damage can be observed in the 
first hours following eccentric exercise with the affected site experiencing muscle swelling, 
contractual protein loss such as desmin and troponin, followed by phagocytic cell invasion 
(Armstrong, 1990; Stephan Sorichter, et al., 1997).   
 
The first phase of exercise induced skeletal muscle injury is the initiating event.  While this phase 
is poorly understood, hypothetical postulations have centered on either physical or metabolic 
events.  The role that physical damage plays into the initiating event has been postulated to be 
caused by three factors.  First, force production due to eccentric exercise generally exceeds 
maximal isometric force by 100% (Woledge, Curtin, & Homsher, 1985).  Secondly, the area of 
force to active fiber ratio during eccentric contractions compared to isometric contractions is 
greater (T. A. McMahon, 1984).  Finally, it has been shown that the number of cross bridges 
decreases as lengthening velocity of muscle increases (1984). The metabolic initiating 
mechanism follows that the muscle is not damaged by mechanical but by disruption of metabolic 
processes such as lack of ATP availability that induces intracellular calcium overload.  Support for 
this theory has been offered by studies that have induced structural changes similar to exercise 
induced muscle damage in resting muscle in rats after ischemia (Mäkitie & Teräväinen, 1977).  
However, studies have shown that greater energy expenditure in rats does not correlate with 
increasing muscle damage suggesting that muscle damage does not correlate with metabolic 
demands (J Komulainen, Takala, & Vihko, 1995).   
 
The initial event also produces temporary force loss, which occurs immediately after the initial 
event and lasts several days following muscle-damaging exercise (Clarkson, Nosaka, & Braun, 
1992).  The cause of force loss has been attributed to damage to the sarcoplasmic reticulum 
delaying the restoration of normal calcium levels and as a consequence impaired force 
generation (Clarkson, et al., 1992).  The second hypothesis to explain force loss is the loss of 
overlap between the actin and myosin filaments due to the longer distance that sarcomeres must 
travel during downhill running (Eston, et al., 1995).  Force loss during eccentric exercise is 
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correlated to the relative muscle length with greater force losses occurring at longer muscle 
lengths (Newham, et al., 1988). 
 
Regardless of whether the initiating event is physical or metabolic, the next step in the initiating 
event is disturbance in intracellular calcium homeostasis.  For example, downhill walking was 
shown to concentrate calcium in damaged muscles of rats (Duan, Delp, Hayes, Delp, & 
Armstrong, 1990).  Cytosolic calcium accumulation has been shown to be the result of either 
membrane damage through micropuncture or passive muscle stretch in rats (Armstrong et al., 
1993; Carpenter & Karpati, 1989).  Increased free cytosolic calcium accumulation has been 
implicated in disruption of mitochondrial ATP production and sarcoplasmic reticulum, increased 
protease and phospholipase activity (Armstrong, Warren, & Warren, 1991; Reddy, Etlinger, 
Rabinowitz, Fischman, & Zak, 1975).   
 
After accumulation of intracellular calcium, muscle swelling is one of the most visible responses 
to muscle damage after the initial event.  Swelling is the result of an influx of water into the 
muscle cell and exacerbated after eccentric muscle damage (Jan Friden, Sfakianos, Hargens, & 
Akeson, 1988).  Regulation of water volume is complex and depends on increased capillary 
permeability, which allows serum proteins to leak into the cell.  The resulting water influx and 
resulting muscle swelling is a prerequisite for fiber necrosis and is proportional to the magnitude 
of muscle damage (J. Komulainen & Vihko, 1995).  Swelling has been implicated in the 
perception of delayed onset muscle soreness (DOMS) after exercise.  It has been suggested that 
swelling creates an increase in local tissue pressure in tight compartments (Bobbert, Hollander, & 
Huijing, 1986).  However, it has been shown that DOMS preceded cellular water influx in mice 
after eccentric exercise suggesting that swelling is not the cause of DOMS (Bar PR, 1994).        
 
Early structural changes are observable almost immediately after exercise cessation.  Changes to 
the muscle include myofilament disruption through Z line streaming which has been hypothesized 
to result from fracturing of much thinner actin myofilaments (J Friden, Sjjöström, & Ekblom, 1981) 
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and cell cytoskeleton disruption through fracturing of desmin linker proteins which occurs within 
15 minutes of eccentric exercise in rabbits (Lieber, Thornell, & Friden, 1996). For example, 
desmin loss after eccentric rabbit dorsiflexion exercise was observed in a significant portion of 
muscle fibers across the muscle that is rapidly repaired up to 72 hours following eccentric 
exercise (J Friden & Lieber, 2001).  Additional changes in histological manifestations of exercise 
induced muscle damage include enlarged mitochondria (Gollnick & King, 1969), myofibril rupture 
(W. T. Stauber, Fritz, & Dahlmann, 1990), and subsarcolemmal vacuolization (Kuipers, et al., 
1983) with short periods of eccentric exercise producing no changes to the ultrastructure or the 
metabolic processes of the mitochondria.  During this period, the mitochondrial energy production 
decreases as evidenced by an increase in hydrogen ion concentration between the inner and 
outer membrane and a mitochondrial temperature decrease (Jennings & Ganote, 1976; Kloner, 
Ganote, Reimer, & Jennings, 1975). 
 
Secondary changes to the muscle ultrastructure occur as soon as two hours post eccentric 
muscle damage and include proteolytic and lipolytic breakdown of muscle proteins and 
membrane lipids which are mediated by the damaged muscle cell (Armstrong, 1990).  Following 
autolytic destruction, neutrophils invade the area and phagocytize dead tissue and release 
cytotoxic factors such as reactive oxygen species which accelerate tissue destruction and alter 
the basement membrane permeability promoting further invasion of inflammatory cells to the 
damaged area (Movat, Cybulsky, Colditz, Chan, & Dinarello, 1987; Vihko, Rantamäki, & 
Salminen, 1978). In addition to neutrophils, monocytes differentiate, invade and phagocytize dead 
tissue after 24 hours of strenuous exercise in humans (Hikida, Staron, Hagerman, Sherman, & 
Costill, 1983). These changes cause an efflux of proteins into the extracellular space such as 
lactate dehydrogenase and creatine kinase following exercise (Armstrong, et al., 1983).  These 
cytoplasmic enzymes are large and are normally unable to cross the cell membrane (Maughan et 
al., 1989). The increase in intracellular protein concentration in the blood may result from the 
disruption of the sarcolemma, allowing the intercellular proteins to diffuse down their 
concentration gradients and out of the cell (Maughan, et al., 1989).  These events, while 
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traumatic for the cell, may benefit tissue regeneration by producing regeneration components that 
help tissue reconstruction through necrotic fiber phagocytosis and autophagocytosis of surviving 
fibers (Salminen, 1985).  
 
Degeneration necrosis of the muscle tissue is followed by the regeneration phase that occurs four 
to six days after the initial damage.  Muscle cell repair begins with satellite cell activation in 
exercised muscle with growth factors controlling myoblast-myotube fusion that results in myofiber 
maturation and proliferation of mitochondria (Florini, Ewton, & Magri, 1991; Myllyla, Salminen, 
Peltonen, Takala, & Vihko, 1986).  In the soleus muscle in rats, maximal satellite cell proliferation 
occurs 24 hours after an acute bout of eccentric exercise (Darr & Schultz, 1987).   Additionally, 
the muscle adapts as evidenced by an increase in sarcomere number in muscle fibers leading to 
a shift in the optimum length of the muscle for active tension protecting the muscle against future 
injuries (Proske & Morgan, 2001). 
 
The damage repair process appears to provide resistance to future insults in both animals and 
humans (P. M. Clarkson, Byrnes, Gillisson, & Harper, 1987; Schwane & Armstrong, 1983).  It is 
believed that training creates a minimization of morphological changes, reduced inflammation, 
preservation of maximal force as evidenced by decreases in plasma levels of intracellular muscle 
proteins, and DOMS attenuation compared to the untrained state (J Friden, Sjöström, & Ekblom, 
1983; Sacco & Jones, 1992).  These adaptations appear to be the result of improved coordination 
and reorganization of the muscle fiber contractile apparatus due to increases in sarcomere 
length, synthesis of Z band proteins and reinforcement of intermediate filaments such as desmin 
(1983). 
 
Quantifying muscle damage has proceeded through a number of indirect methods such as 
estimation of pain, decrease in maximal muscle force, and impaired range of motion (P. M. 
Clarkson, Nosaka, & Braun, 1992; Stauber, et al., 1990; Stauber WT & B., 1988).  It has been 
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shown that muscle damage correlates well with some intracellular proteins such as troponin, fatty 
acid binding protein, myoglobin, and creatine kinase. 
 
Troponin is a protein found only in cardiac and skeletal muscle that is integral to muscle 
contraction and is an often-used diagnostic marker of myocardial infarction and heart muscle cell 
death.  The binding of calcium to troponin causes a conformational change exposing binding sites 
allowing myosin-actin cross bridge formation, allowing contraction of the muscle.  Troponin 
isoforms differ between muscle tissues with cTN1 the predominate form in cardiac muscle and 
sTN1 found in skeletal muscle.  Skeletal muscle troponin I has been used very rarely in exercise 
studies due to the difficulty of ELISA preparation.  However the advent of commercially available 
kits has made performing these assays much easier and much less time consuming.  The first 
study to use skeletal troponin I as an indicator of muscle damage was Storichter et. al. (1997) 
who found it to be a highly reliable indicator of muscle damage (Stephan Sorichter, et al., 1997).   
 
Fatty Acid Binding Protein 3 (FABP3) is a 15 kilo Dalton cytoplasmic protein with highest 
concentrations found in cardiac and type I skeletal muscle fibers.  FABP3 plays a role in fatty acid 
metabolism by transporting fatty acids from the cell membrane to mitochondria for oxidation and 
plays a role in regulating cell growth and proliferation (Kleine, Glatz, Van Nieuwenhoven, & Van 
der Vusse, 1992).  FABP3 is released from cardiac myofibrils following cardiac muscle damage 
by ischemic episodes and is used with troponin to diagnose myocardial infarction (Azzazy, 
Pelsers, & Christenson, 2006).  Recently Pritt et. al. (2008) found that FABP3 was the most 
useful individual biomarker for skeletal muscle damage based on concordance, sensitivity, and 
predictive value and had greater diagnostic value than creatine kinase and aspartate 
transaminase (Pritt et al., 2008). 
 
 
Myoglobin is an iron and oxygen-binding protein found in cardiac, type I and type II skeletal 
muscle tissue and any appearance in the blood is attributed to muscle cell membrane rupture.  
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Myoglobin is a diagnostic marker for muscle injury, making it a potential marker for myocardial 
infarction.  However since myoglobin is cleared from the kidney this assumes the rates for 
production and clearance are equal.  Unequal rates affect the myoglobin plasma concentration 
resulting in an over or underestimation of the extent of EMID/DOMS (Tiidus, 2008). 
 
Creatine Kinase has been used as a marker of muscle damage and is an enzyme that catalyses 
the conversion of creatine and consumes adenosine triphosphate to create phosphocreatine and 
adenosine diphosphate and has many different isoforms found in a variety of tissues (Goldblatt, 
1969).  Typical measured values of creatine kinase in the blood are between 10 - 120 
micrograms per liter (mcg/L) which peaks 12-24 hours post eccentric muscle damage (Byrnes et 
al., 1985).  A specific isoform of creatine kinase, CK-MM is found in skeletal muscle and has been 
shown to be an indicator of muscle damage in males after eccentric biceps contractions despite 
no change in total creatine kinase levels (Apple, Hellsten, & Clarkson, 1988). Creatine kinase’s 
ability to accurately estimate the extent of EIMD/DOMS has been called into question by recent 
studies.  For example, there are large differences between older and younger men in the extent 
of muscle damage determined by muscle biopsy following eccentric exercise despite no 
significant difference in creatine kinase activity (Manfredi et al., 1991). Further, Van der Meulen 
et. al. (1991) found that creatine kinase levels overestimate tissue damage as determined by 
muscle biopsy in rats after a downhill run (Van der Meulen, Kuipers, & Drukker, 1991).  
 
Strategies to minimize EMID 
Since muscles are subjected to extreme stress during eccentric exercises, minimization of 
damage has centered on increasing membrane flexibility to maintain a balance between a rigid, 
ordered inflexible structure and completely fluid nonviscous liquid. Membrane flexibility enhances 
and increases membrane integrity retaining toxic cellular contents inside the cell and thereby 
attenuating the inflammation response.  Unsaturated fatty acids increase membrane flexibility 
while saturated fatty acids increase rigidity.  It has been shown that incorporation of n-3 PUFAs 
into the ER of yeast cells increased resistance to cellular stress (Deguil et al., 2011).  Forces 
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found in exercising muscle such as shear stress exert various metabolic effects on endothelial 
cells by up regulating genes controlling membrane fluidity through fatty acid catabolism and 
membrane incorporation (Qin et al., 2007).  Cell membranes have optimal fluidity for function and 
act as shock absorbers thereby distributing force evenly minimizing fractured cells and 
cytoplasmic leakage (Chien, 2008).  Supplementation of n-3 PUFAs has resulted in a decrease in 
intracellular biomarkers and inflammatory biomarkers in resting men suggesting increased 
membrane integrity (Richard J Bloomer, Douglas E Larson, Kelsey H Fisher-Wellman, Andrew J 
Galpin, & Brian K Schilling, 2009).   
Exercise related muscle damage and free radical mechanisms 
There are many potential sites for free radical generation during exercise as well as many 
enzymes that assist in free radical neutralization in skeletal muscle.  Since the mitochondria is a 
large producer of reactive oxygen species, oxidative skeletal muscle fibers are subjected to large 
changes in oxygen flux during aerobic exercise which has been thought to increase skeletal 
muscle tissue damage (Sen, 1995).  Minimization of reactive oxygen species is enhanced in 
skeletal muscles through incorporation of antioxidants and enzymes in skeletal muscle tissue. 
Current literature suggests free radical generation is increased during exhaustive aerobic 
exercise but does not significantly cause damage to the surrounding muscle tissue.  However 
skeletal muscle is very susceptible to secondary damage caused by the immune system during 
eccentric exercise and secondary tissue damage caused by the resulting immune response 
(Reznick, Packer, Sen, Holloszy, & Jackson, 1998). 
DNA in muscle cells is under the continuous assault of reactive oxygen species and lipid peroxide 
radicals, which can interact with DNA causing damage which leads to mutations and if severe 
enough, cell death.  DNA’s vulnerability to reactive oxygen species results from prevalence of 
double bonds in DNA bases that radicals can easily add to and labile hydrogen atoms that can be 
abstracted through the deoxyribose sugar backbone, leaving a radical formation at the reacted 
carbon on the DNA strand which reacts with molecular oxygen leading to a DNA strand break 
(Povirk, 1996).  In order to maintain proper function, DNA is repaired by various protein kinases 
resulting in 8-Oxo-2'-deoxyguanosine (8-OHdG) which is most often used to assess the extent of 
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DNA damage in skeletal muscle (Park & Ames, 1988).  For example Hartman el. (1994) found 
that DNA damage in rats by running on a treadmill for 45 minutes peaked at 24 hours after 
running and returned to normal levels 72 hours postexercise (Hartmann, Plappert, Raddata, 
Grünert-Fuchs, & Speit, 1994).  Regular exercise such as swimming and distance running has 
been shown to decrease levels of nuclear 8-OHdG along with increases of plasma antioxidant 
concentrations (Inoue, Mu, Sumikawa, Adachi, & Okochi, 1993; Pilger et al., 1997).  It seems that 
DNA damage from radicals can only be detected when exercise is exhaustive such as marathons 
and ultramarathons (Gomez-Cabrera et al., 2006; Keizo Umegaki, Daohua, Sugisawa, Kimura, & 
Higuchi, 2000).  Sacheck al el (2003) studied 12 weeks of vitamin E (1000 IU/day) 
supplementation on biomarkers of oxidative stress in healthy men.  Muscle damage was induced 
at -15% downhill running for 45 min at 75% VO2max and blood samples were obtained at 
baseline, 0, 6, 24, and 72 hours postexercise to determine the extent of DNA damage. The study 
found that leukocyte 8-OHdG concentrations were unaffected by exercise in both control and 
experimental groups. 
 
Prostaglandin metabolism generates reactive oxygen species through intermediates activated 
during excessive contractile activity (A McArdle, Edwards, & Jackson, 1991).  A precursor to 
prostaglandins, arachidonic acid, can be activated through lipoxygenase enzymes and generates 
reactive oxygen species which have been implicated in skeletal muscle damage in female Wistar 
rats (Jackson, Wagenmakers, & Edwards, 1987). 
 
However the role of prostiglandins in exercise muscle damage is not clear.  Kuipers et. al. (1985) 
used Flurbiprofen (90 mg/day), a cyclooxygenase-inhibiting drug, to assess the role of 
prostaglandin metabolism on subjective symptoms of soreness and eventual structural changes 
in muscle during a 30 minute cycle ergometry session at 80% VO2max. Muscle biopsies taken at 
baseline, immediately after, and 24 hours after exercise were used to examine muscle structural 
changes in conjunction with plasma levels of muscle enzymes. No significant enzyme release 
was noticed in any of the subjects and structural changes were restricted to the mitochondria. No 
 32 
statistical difference in subjective soreness was observed between groups suggesting that at this 
workload and mode of exercise prostaglandin metabolism does not play a major role in exercise-
induced muscle soreness and structural damage. 
 
It has been suggested that failure of muscle calcium homeostasis following exercise results in the 
free radical formation through activation of calcium dependent proteases such as Calpain and 
phospholipase A2 which cleave intracellular muscle and membrane phospholipids respectively.  
Additionally the mitochondria eventually fail to produce ATP resulting in increased superoxide 
production from metabolic free radical generation due to calcium overload (Anne McArdle & 
Jackson, 1997).  However these mechanisms are not believed to be the primary cause of muscle 
damage as failure of calcium homeostasis occurs secondary to an increase in free radical activity 
in biological tissue (Anne McArdle & Jackson, 1997).  
 
The most likely cause of muscle tissue damage after endurance exercise by reactive oxygen 
species occurs by invading macrophages and other phagocytic white cells from the blood and 
interstitial space (Armstrong, 1986).  The phagocytic process results in substantial amounts of 
oxygen radical release and has been shown to be essential for efficient preparation of muscle 
tissue regeneration and destruction of necrotic tissue (Fantone & Ward, 1985).  Since this 
response is non specific and occurs in biological tissue, an increase in reactive oxygen species 
does not necessarily correlate with an increase in tissue damage and must be used in consort 
with other markers of muscle damage such as inflammatory markers and intracellular proteins to 
assess the extent of post exercise damage (Cannon et al., 1991). 
Inflammatory process  
Inflammation is a general response to tissue injury such as muscle damage and designed to 
minimize further damage and promote healing.  Symptoms of inflammation include pain, swelling, 
redness, and reduced function.  The process of inflammation (figure 1) following muscle damage 
is characterized by an influx of fluid and neutrophils into the tissues within the first few hours 
following injury.   
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Figure 1: Proposed inflammatory sequence: taken from Garrett et al. (2000) 
Next macrophages are recruited to the injured site, remove cellular debris, and secrete 
chemokines and cell adhesion molecules that aide in the amplification and ultimately termination 
of the inflammatory response.  Cytokines serve as emergency signalling molecules that 
coordinate signaling among many different types of cells including leukocytes, stem cells, 
progenitor cells, endothelial cells, and hepatocytes.  TNF-α, IL-1, and IL-6 are three important 
cytokines in muscle damage.  TNF-αis a 212-amino acid-long transmembrane protein that 
regulates immune cells and has been shown to induce cell death, fever, and inflammation with 
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disregulation resulting in various inflammatory diseases such as cancer and inflammatory bowel 
disease (Brynskov et al., 2002; Locksley, Killeen, & Lenardo, 2001).  TNFαand IL-1 are 
produced first by macrophages resident in the injured tissue and are strong inducers of IL-6 
production (Mastorakos, Chrousos, & Weber, 1993). IL-6 is a signaling protein when produced by 
monocytes or macrophages and elicits a pro-inflammatory response while muscle production 
elicits an anti-inflammatory response and is independent of a preceding TNF-alpha response or 
NF-kB activation (Brandt & Pedersen, 2010).  Plasma concentrations of IL-6 increase up to 100-
fold from baseline post eccentric exercise resulting in a delayed peak and a much slower 
decrease of plasma IL-6 during recovery (Bente K Pedersen, 2013). 
 
Muscle biopsies showed IL-6 production increased within the muscle immediately after strenuous 
exercise such as high intensity interval or marathon running (Nehlsen-Cannarella et al., 1997; 
Papanicolaou et al., 1996).  Neutrophils are the first leukocyte population to respond to the 
cytokine “alarm call” and are responsible for debris phagocytosis by binding to compliment 
immunoglobulins; release lysosomal proteases which degrade intramuscular proteins; and 
damage lipid membranes with reactive oxygen species produced by NADPH oxidase (Epstein & 
Weiss, 1989).  These actions, if left uncontrolled can cause disease since they can target both 
diseased and healthy tissue.  These destructive processes are regulated by acute phase proteins 
such as C-reactive protein which are produced in the liver in response to eccentric exercise 
(Colley, Fleck, Goode, Muller, & Myers, 1983).  The magnitude of tissue damage is correlated 
with C-reactive protein release with 88 kilometer ultra marathon runners experiencing levels 
equivalent to a small cardiac infarction (Strachan, Noakes, Kotzenberg, Nel, & De Beer, 1984).  
Accumulations of neutrophils in muscle fibers have been reported after high force eccentric 
contractions within minutes after injury with resolution occurring within five to seven days 
(Fielding et al., 1993; Round, Jones, & Cambridge, 1987).  Neutrophil activity is modified by 
exercise with oxidative capacity decreased and phagocytic capacity increased in response to 
strenuous exercise (Pyne, 1994; Rincon, 1994).  Leukocyte recruitment into injured tissue from 
the vasculature is accomplished through cell adhesion molecules, which arrest leukocyte 
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movement in the vasculature and facilitate cell invasion.  During strenuous exercise it has been 
found that cells leave circulation more readily due to the up regulation of certain cell adhesion 
molecules such as VCAM-1 and ICAM-1 (L. Smith et al., 2000).   
 
After macrophage infiltration the final phase in the inflammatory process is necrosis, which 
releases intracellular contents into the microenvironment resulting in an exacerbated 
inflammatory response (Cohen, 1993).  Necrosis is circumvented by apoptosis which is a 
sequential destruction of the cell where membrane integrity is never lost and the 
microenvironment is protected from harmful intracellular components such as hydrogen peroxide, 
enzymes, and neutrophil granules with cytokines such as IL-6 promoting cells apoptosis in 
neutrophils resulting in eicosanoid and cytokine production cessation (Afford, Pongracz, Stockley, 
Crocker, & Burnett, 1992; Epstein & Weiss, 1989). 
 Strategies to minimize Inflammation 
 
As far back as the Grecian times, myrtle leaves and willow bark were used to minimize the 
undesirable effects of inflammation (McMurry, 2004).  In modern times, athletes have sought to 
minimize inflammation and maximize training by using NSAIDs.  NSAIDs minimize inflammation 
by acting as non-selective inhibitors of the enzyme cyclooxygenase (COX).  COX catalyzes 
prostaglandin and thromboxane formation from arachidonic acid which is an unsaturated fatty 
acid precursor cleaved from the cell membrane by phospholipase A2.  Arachidonic acid is non 
polar and as a consequence readily diffuses in and out of cells and serves as both an intra and 
intercellular messenger (J. Williams, Errington, Lynch, & Bliss, 1989).  Prostaglandins also serve 
as signaling molecules that mediate the inflammatory process and are released from skeletal 
muscle that has been subjected to excessive contractile activity (A McArdle, et al., 1991). 
Prostaglandin metabolism generates reactive oxygen species (ROS) which can lead to 
membrane destruction (Halliwell & Gutteridge, 1985).  Additionally, extracellular arachidonic acid 
leaking from damaged muscle cells can serve to activate neutrophils resulting in tissue 
destruction by lipid peroxidation through ROS formation.  Lipid peroxides form due to the 
generation of ROS by the mitochondria and pro-oxidant enzymes on the neutrophils such as 
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NADPH oxidase that degrade the lipids of the cell membrane as evidenced by increased 
concentrations of intracellular lipid 
peroxides, which are products 
normally formed from 
polyunsaturated fatty acids 
reacting with free radicals 
(Jenkins, Martin, & Goldberg, 
1983).  It is believed that ROS 
activates the NF-kB pathway 
which initiates the third phase of 
phagocytic destruction by the 
immune system (Whitehead, Yeung, & Allen, 2006).  NF-kB is a transcription factor that regulates 
pro inflammatory cytokine expression 
such as TNF-alpha, IL-1, and IL-β (Kumar & Boriek, 2003) (Whitehead, et al., 2006).  TNF-alpha 
can cause a positive feedback loop in the mitochondria leading to a chain reaction of ROS 
production causing increased lipid peroxidation and inflammation (Reid & Li, 2001).  ROS can be 
produced by inflammatory cells and can be decreased by the release of nitric oxide by vascular 
endothelial cells (Privat et al., 1997).  While multiple versions of the COX enzyme exist, only 
COX2 is believed to play a role in inflammation.  NSAID treatment has been successfully used to 
minimize inflammation and DOMS in athletes following eccentric muscle damage (J. M. Peterson 
et al., 2003).  However, inhibiting the inflammatory process with NSAIDs may not be beneficial to 
long term training performance and can lead to satellite cell quiescence and attenuated 
performance gains following training (Mikkelsen et al., 2009).     
EPA and DHA supplementation on Inflammation 
DHA, EPA, and arachidonic acid are all involved in maintaining cell membrane structure and 
function with arachidonic acid being the main components in terrestrial mammals (Sargent, Bell, 
McEvoy, Tocher, & Estevez, 1999). Altering the percentage of these components changes the 
membrane structure.  N-3 PUFA supplementation increases membrane fluidity allowing more 
Figure 2: Inflammatory pathways taken from Calder (2002) 
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efficient nutrient exchange (Freeman et al., 2006; Kidd, 2007). In neurons increased membrane 
fluidity is associated with faster neural transmission and more efficient biochemical performance 
resulting in improved higher brain functions including sense of well-being, reactivity, attention, 
cognitive performance, and mood (G. Fontani et al., 2005). 
 
In addition to reducing free radical production and membrane fluidity, supplementation can 
attenuate eicosanoid production by replacement of n-6 PUFAS with less inflammatory n-3 
PUFAs. Eicosanoid production regulates inflammation and originates from 20-carbon n-3 PUFAs. 
Inflammatory cells contain high proportions of n-6 PUFAs incorporated into the phospholipid 
membrane and low proportions of other 20-carbon PUFAs and as a consequence when lipid 
peroxidation occurs arachidonic acid is the major substrate for eicosanoid synthesis. The relative 
proportion of these fatty acids in the membrane can be altered through dietary modifications.  
Increases in dietary consumption of n-6 PUFAs or precursors such as linoleic acid have 
increased inflammation compared to n-3 PUFAs through increased arachidonic acid and 
inflammatory mediator production such as PGE2 and LBT4 (Kelley, Taylor, Nelson, & Mackey, 
1998; L. D. Peterson et al., 1998; F Thies et al., 2001).  Despite the increase in inflammatory 
mediators, production of TNF-α, IL-1β, or IL-6 by mononuclear cells did not increase or alter 
superoxide production (F. Thies et al., 2001).  Increased dietary consumption of n-3 PUFAs such 
as DHA and EPA increased the composition of these fatty acids in the phospholipid membrane 
and decreased the percentage of n-6 PUFA in the phospholipid membrane.   Additionally the 
same study found a decrease in eicosanoid mediator production of PGE2, thromboxane B2, LTB4, 
and 5-hydroxyeicosatetraenoic acid (Caughey, Mantzioris, Gibson, Cleland, & James, 1996; 
Endres et al., 1989; Lee et al., 1985).  Omega fatty acids can also act as a substrate for both 
COX and 5-LOX, giving rise to eicosanoids such as LTB5, LTE5, and PGE3.  These compounds 
have different structures than those formed from arachidonic acid and as a consequence are less 
inflammatory than those formed from arachidonic acid (Goldman, Pickett, & Goetzl, 1983; Lee, et 
al., 1985; Sperling et al., 1993; von Schacky, Kiefl, Jendraschak, & Kaminski, 1993).  Additionally, 
EPA can generate anti-inflammatory compounds such as D and E series resolvins from COX2 (C. 
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N. Serhan, Arita, Hong, & Gotlinger, 2004; Charles N Serhan et al., 2000).  In addition to their anti 
inflammatory properties, n-3 PUFA’s can enhance endogenous antioxidant defense systems such 
as glutathione reductase and γ-glutamyl-cysteinyl ligase (Arab, Rossary, Flourié, Tourneur, & 
Steghens, 2006).  DHA and EPA incorporate into the phospholipid bilayer of cells where they 
displace arachidonic acid. Arachidonic acid causes ROS generation through COX2 and xanthine 
oxidase inflammatory pathways (Marnett, Rowlinson, Goodwin, Kalgutkar, & Lanzo, 1999).  
These inflammatory pathways can be inhibited by DHA and EPA administration and the 
chemoattractants derived from EPA are less potent than those derived from arachidonic acid 
(Kim & Chung, 2007; Mayer et al., 2003).  Recently, it was shown that EPA and DHA attenuated 
TNF-α stimulated monocyte protein gene expression by interacting with key gene inflammatory 
pathways such as ERK and NF-κB (Encarnacion et al., 2011; Epstein, Barnes, & Karin, 1997).  
EPA and DHA supplementation reduced oxidative stress, inflammation and fibrosis through the 
reversal of inflammatory and oxidant pathways in patients with kidney disease, heart failure, 
diabetes, hypertension, and dyslipidemia (An, Kim, Cho, & Vaziri, 2009; Bouzidi et al., 2010; 
Matsumoto, Nakayama, Ishida, Kobayashi, & Kamata, 2009; Peake, Gobe, Fassett, & Coombes, 
2011; Woodman et al., 2002).  Despite anti-inflammatory properties, n-3 PUFA supplementation 
has not improved performance of endurance athletes compared to placebo (Nieman, Henson, 
McAnulty, Jin, & Maxwell, 2009). 
 Muscle Damage Exercise Models 
Damage in skeletal muscle can be elicited through eccentric exercise by downhill running.  For 
aerobic endurance exercise downhill running is commonly used in literature as a noninvasive way 
of eliciting muscle damage.  Variations of maximal oxygen up take and gradient have been used 
as a way to achieve damage during the downhill run. Literature suggests that steeper gradients 
and longer durations have been highly correlated with increased skeletal muscle damage (Tiidus, 
2008).  Studies have varied speed and gradient with the most reliable method to elicit symptoms 
of EIMD/ DOMS have been to have subjects run at a -16% gradient for at least 20 minutes 
(Stephan Sorichter, et al., 1997; Tiidus, 2008).   
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The mechanism of action is debated however it is thought that during the eccentric phase of 
movement of downhill running, the muscle absorbs energy by stretching and absorbs mechanical 
energy and as a consequence results in increased force production (LaStayo, Ewy, Pierotti, 
Johns, & Lindstedt, 2003; Lindstedt, LaStayo, & Reich, 2001). Muscle damage occurs during 
running while the muscles are lengthening after the foot touches the ground and center of mass is 
decelerating (Armstrong, Ogilvie, & Schwane, 1983).  During downhill running, the joint angle is 
greater and the muscle has to work eccentrically at a greater length requiring more work at its 
longer length resulting in greater knee extensor muscle group strain compared to level running 
(Newham, Jones, Ghosh, & Aurora, 1988).  Additionally, downhill running contributes to an 
increase in intramuscular pressure in a non-compliant muscle compartment, compared with 
concentric exercise that affects nerve nocioreceptors creating a sensation of pain which is 
thought to cause the sensation of DOMS (Eston, Mickleborough, & Baltzopoulos, 1995).  
Maximal force loss and Muscle damage 
Skeletal muscle injury results from trauma and can affect the performance of contractions 
themselves, especially eccentric contractions. Muscle injury results in impaired muscle function 
that includes decreased joint range of motion, increased swelling, and prolonged strength loss. 
Strength losses following eccentric exercise in excess of 40–50% baseline values with complete 
recovery occurring up to 30 days from the initial insult.  Because of the implications of long lasting 
injuries on training and performance, athletes have sought to minimize injuries by utilizing various 
techniques such as supplementing with n-3 PUFAs.   
 
The cause of muscular force loss post eccentric exercise has been debated with one theory 
suggesting force loss was a result of a physical disruption or alteration of force-generating and 
transmitting structures in muscle such as the actin or myosin filaments.  Evidence to support this 
theory has traditionally come from histological lesions associated with this type of injury such as A 
band disruptions and z-line streaming which result in decreased force production (Tiidus, 2008).  
While there is some evidence to support the theory, it has been shown the myofilament disruption 
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typically accounts for 34% of strength loss in single fiber preparation models indicating that there 
is a more significant factor that affects force loss after eccentric exercise (Reznick, et al., 1998). 
 
Another theory has focused on the inability to activate the actin and myosin microfilaments 
through the excitation contraction coupling.  The excitation contraction-coupling pathway begins 
with acetylcholine release by the alpha-motor neuron at the neuromuscular junction.  An action 
potential is generated which passes along the plasmalemma until it goes deep into the fiber via 
the t-tubule. T-tubular membrane depolarization induces calcium release from the sarcoplasmic 
reticulum into the cytosol, where it binds to troponin to initiate the actin myosin cross bridges. 
Warren and coworkers found that disruption of calcium homeostasis affects force production after 
muscle damage in mouse soleus muscles. After injury, muscles were injected with caffeine that 
promoted calcium release from the sarcoplasmic reticulum thereby increasing intracellular 
calcium levels. Any observed force loss after caffeine injection would be interpreted as intrinsic 
dysfunction of the sarcoplasmic reticulum or excitation contraction coupling rather than a physical 
disruption of the actin and myosin microfilaments.  The study found that after post muscle 
damage the caffeine-elicited force produced by the injured muscles was not statistically different 
from the non damage control muscle suggesting that force loss was due to failure of the 
excitation-contraction coupling (Warren, et al., 1993). 
 
Linker proteins such as desmin have been proposed as a cause of the loss of force in skeletal 
muscle post eccentric exercise.  Desmin connects the sub-sarcolemmal cytoskeleton with the z 
disk and laterally connects the z disks together which maintains cellular structural integrity during 
contraction (Z. Li et al., 1997; Paulin & Li, 2004).  There is little evidence to suggest that force 
loss immediately after exercise is caused by desmin loss since the rate of protein degradation of 
myofilament protein content is not altered until 6 hours post muscle damaging exercise (Ingalls, 
Warren, Williams, Ward, & Armstrong, 1998; Lowe, Warren, Ingalls, Boorstein, & Armstrong, 
1995).  While not a cause of immediate force loss, there is a progressive loss of contractile 
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protein content beginning 1 day and continuing until 5 days after muscle damage suggesting a 
later role in force loss (Lowe, et al., 1995). 
 
Rajabi et al. (2013) showed that 30-day n-3 PUFA supplementation (2000 mg/day) attenuated 
force loss post eccentric muscle damage in 20 healthy subjects compared to control. Leg presses 
were performed at 75% of one-repetition maximum with 4 sets of 20 repetitions with a 180 
second rest period between sets.  Voluntary contractile force was measured immediately, 24, 48 
and 72 hours after exercise.  The results showed that there were significant differences between 
the control and treatment groups 48 and 72 hours post muscle-damaging exercise with the 
treatment group experiencing attenuation in force loss compared to control (Rajabi, Lotfi, 
Abdolmaleki, & Rashid-Amiri, 2013).   
 
These results are contradicted by Pumpa et. al. (2012) who found that force attenuation after 
muscle damaging exercise was unaffected by PCSO-524™ supplementation compared to 
control.  Twenty well-trained males were randomly assigned to consume PCSO-524™ (200 
mg/day) or placebo for 8 weeks prior to a downhill treadmill run.  Maximal force was measured by 
isometric torque at 60º/second for 8 maximal force contractions on the right and left legs, 
countermovement jump and squat jump.  The results found no significant decrease for time or 
group effects in force production following exercise induced muscle damage for both the 
countermovement jump and squat jump suggesting that PCSO-524™ was ineffective at 
attenuating force loss compared to placebo. The study also showed that there was a non-
significant decrease in force production after the downhill run in both placebo and treatment 
groups in the left leg and a decrease in force production in the treatment group.   
DOMS 
Delayed onset muscle soreness (DOMS) is transient perception of muscular pain and is often 
combined with tenderness and stiffness that results from muscle trauma especially from intense 
or unaccustomed eccentric exercise such as downhill running, resistive cycling, and ballistic 
stretching (L. L. Smith, 1991).  The causes of DOMS have been debated and research has 
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centered on nociceptor compression by muscle spasms; excessive lactic acid accumulation; 
disrupted z-lines; connective tissue strain; inflammatory cell infiltration and resulting nociceptor 
activation from edema; and excessive calcium accumulation leading to inhibition of ATP 
generation, and activation of protease and phospholipase enzymes (Armstrong, 1984; de Vries, 
1966; KT Francis & Hoobler, 1987; Gulick & Kimura, 1996; Hough, 1902).   
 
While none of these theories is thought to be entirely responsible for DOMS, current literature 
suggests an integrated theory beginning with disruption of structural proteins in muscle fibers, 
particularly at the weakened z-lines during eccentric exercise damages the sarcolemma inhibiting 
cellular respiration and increasing lypolytic and proteolytic enzyme activation.  These enzymes 
disrupt the plasma membrane allowing intracellular contents to leak into the interstitial space that 
attracts monocytes that differentiate into macrophages within 12 hours of muscle damage.  The 
macrophages produce prostaglandin (PGE2), which sensitizes nerve endings to mechanical, 
chemical or thermal stimulation.  Additionally the products from active phagocytosis and cellular 
necrosis such as histamine, potassium and kinins in addition to elevated pressure from tissue 
edema further activate nociceptors within the muscle (Smith Jr & Jackson, 1990).  One of the 
limitations in using DOMS in muscle damage assessment is the high rate of non responders with 
one study reporting that one-third of subjects undergoing maximal eccentric contractions 
experienced no "meaningful'' muscle soreness (Sayers & Clarkson, 2001). 
 
DOMS can affect athletic performance and may result in altered muscle function and joint 
mechanics which may lead to a reduction in performance and less than optimal training intensity.  
Significant reductions in joint range of motion have been reported after repetitive eccentric 
resistance exercise (Kennon Francis & Hoobler, 1988).  Significant reductions in strength and 
power parameters during DOMS with peak torque deficits occurring 24–48 hours after DOMS-
inducing exercise and are more profound and persistent during eccentric testing and may require 
up to 8–10 days to return to baseline levels.  Evans et al. (1990) found isokinetic eccentric peak 
torque of the elbow flexors decreased immediately after (44%), 24 hours (39%) and 48 hours 
 43 
(32%) following repetitive eccentric contractions using an isokinetic dynamometer set at 
60°/second. By 14 days, eccentric peak torque had returned to normal (D. Evans, Smith, Chenier, 
Israel, & McCammon, 1990). 
 
Treatment of DOMS typically involves treatment with NSAIDs which inhibit arachidonic acid 
metabolism via the cyclooxygenase pathway and prevent endoperoxide and prostaglandin 
production reducing the inflammatory response attenuating muscle edema and intramuscular 
pressure which are thought to be contributing factors to DOMS (S. Hasson, Wible, Reich, Barnes, 
& Williams, 1992; S. M. Hasson et al., 1993).   
 
Omega-3 fatty acids also inhibit prostaglandin production by acting as less inflammatory 
substrates for the COX enzymes thereby reducing membrane destruction and immune response.  
Recently, Tartibian et al. (2009) examined the effect of 30 days of n-3 PUFA supplementation on 
the effects of DOMS after eccentric exercise.  27 men were randomly assigned to one of the 
experimental n-3 PUFA (324 mg EPA and 216 mg DHA), placebo, and control groups.  Knee 
range of motion was determined using goniometry, self-reported levels of lower extremity pain, 
and thigh circumference. Measurements were taken at baseline, immediately after, 24 and 48 
hours after 40 minutes of bench stepping.  The results found that while no differences were 
observed for pain and ROM at baseline, immediately after, and 24 hours after exercise, 
differences were evident in perception of pain and ROM 48 hours after exercise with the n-3 
PUFA group experiencing attenuated pain and loss of ROM. Differences in thigh circumference, 
were evident at 24 and 48 hours after muscle damaging exercise, and there was no difference 
before and immediately after exercise with the control group experiencing a greater increase in 
thigh circumference.  The authors concluded that n-3 PUFA supplementation at this dose can 
effectively reduce the symptoms of DOMS and inflammation (B. Tartibian, B. H. Maleki, & A. 
Abbasi, 2009).   
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Chapter 3: Methods  
Subjects 
Forty untrained males aged 18-26 participated in this study, and were recruited from the local 
Bloomington, Indiana population, with 34 subjects completing the study.  Reasons for subject 
withdrawal included personal issue (1), failure to show (1) inability to obtain blood (3) and 
removed for outliers for DOMS data (2).  Since the menstrual cycle has been shown to affect 
muscle damage, females were not included in this study (Sipaviciene, Daniuseviciute, Kliziene, 
Kamandulis, & Skurvydas, 2013).  Subjects exercised less than 3 times a week for 30 minutes a 
session and had a BMI under 30 kg/m2, blood pressure of less than 140 mmHg/90 mmHg, fasting 
blood glucose of less than 100 mg/dL; and total cholesterol of 200 mg/dL.  Additionally, subjects 
did not have a history of asthma or exercise-induced asthma, COPD, interstitial lung diseases, or 
cystic fibrosis, dyspnea, performed eccentric endurance exercise or participated in a strength 
training program 60 days prior to enrolling in the study, consumption of n-3 PUFAs or anti-
inflammatory medication, history of hip or knee pain, seafood allergies, a familial or personal 
history of cardiovascular disease, ankle edema, tachycardia, known heart murmurs, shortness of 
breath or diabetes.  Additionally subjects were not enrolled if they came from a family that had a 
history of heart disease, tobacco use, or dyslipidemia.  Subjects were not allowed to consume 
fish oil or fish oil products during the study or exercise for more than 3 times a week for 30 
minutes a session.  Diet was monitored to ensure no significant dietary changes occurred during 
the study.  Subjects also documented mood and exercise activity during the study.     
Study Design  
The study lasted over 7 weeks and was divided into pre and post supplementation phases 
(Figure 4).  The pre supplementation phase consisted of baseline measures of muscle damage 
and blood biomarkers. 143 subjects were screened and 40 qualified and were randomly assigned 
to either a treatment or control group with a randomization ratio of 1:1.  34 subjects completed the 
study with 2 subjects being excluded and 6 subjects dropped for failing to comply with the 
requirements of the study.   
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Figure 3: Flowchart of subject participation through the study 
Subjects entered the study on their normal diet and after completing the baseline measures were 
randomly assigned to supplement for 29 days with either 8 capsules of Omega XL® (1 capsule 
contains 50 mg of n‐ 3 PUFA and 100 mg olive oil) or placebo capsules (1 capsule contains 150 
mg olive oil).   PCSO-524™ contains stabilized lipids from the New Zealand green-lipped mussel, 
Perna canaliculus, in combination with olive oil, vitamin E, sterol esters, sterols, polar lipids, 
triglycerides and free fatty acids (including 13% EPA, 21% DHA) (Murphy, Mooney, Mann, 
Nichols, & Sinclair, 2002).  The placebo group of 16 subjects consumed 8 capsules/day 
containing olive oil for four weeks.  A between-subject design was used to avoid the influence of 
the repeated bout effect associated with a within-subject design (McHugh, Connolly, Eston, & 
Gleim, 1999).   
 
Testing was performed in a laboratory setting during the baseline and post supplementation 
periods with supplementation occurring away from the laboratory.  Tests were conducted in the 
human performance and exercise biochemistry laboratories at Indiana University, Bloomington.  
An independent investigator not involved in data collection and having no contact with the 
subjects used a computerized random number generator (Random, http://www.random.org/) to 
create the randomization sequence with a 1:1 placebo/control allocation. 
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Figure 4: Schematic diagram of study protocol showing the pre and post supplementation 
sequential phases of the study.  
Subjects performed a cycle familiarization time trial during the first lab visit.  On the second visit 
(week 2), subjects performed a treadmill VO2 max test.  For the VO2 max test, subjects selected a 
comfortable pace to run at and rested for 5 minutes while being monitored for expired O2 and 
CO2. The test commenced at 0% grade and a speed of 1.6 kph less than the selected speed for 
2 minutes after which time, the speed was increased to the predetermined speed chosen by the 
subject for 2 minutes. After 2 minutes the slope of the treadmill was increased to 4% for 2 
minutes while maintaining a constant speed.  Slope was increased 2% every 2 minutes until 
exhaustion. 
 
On the third visit (week 3), subjects were evaluated for baseline measures of muscle force, range 
of motion, muscle swelling, muscle pain and algometry.  Additionally a blood draw established 
baseline measures of intracellular muscular proteins and inflammatory markers.  All blood draws 
were taken from the antecubital vein of the arm and collected into red top Vacutainer® tubes. The 
tubes were placed on ice for at least 30 minutes before centrifugation at 20°C at 3000 RPM for 15 
minutes.  Serum was allocated to storage tubes and stored immediately at -80°C in multiple 
aliquots.  
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During the 26 day supplementation period, half of the subjects supplemented with the placebo, 
which was an olive oil capsule, and the treatment group supplemented with the Omega XL® 
capsules.  Both groups consumed 8 capsules a day (4 in the morning, 4 in the evening).  Dosage 
was carefully chosen based on studies that showed an effect with 400 mg n-3 PUFA/day 
(Tecklenburg-Lund et al., 2010).  On the fifth visit, (47th day of the study), functional measures of 
exercise-induced muscle damage were assessed and blood drawn prior to the downhill muscle 
damaging exercise.  
 
After the muscle damaging exercise, subjects rested for 2 hours.  After two hours blood was 
drawn.  Muscle force, range of motion, muscle swelling, knee extensor pain, algometry and blood 
was collected 24, 48, 72, and 96 hours after muscle induced damage.  
 
Measurements 
Maximal Voluntary Contraction 
Muscle force protocol required subjects to contract their quadriceps at a knee angle of 80°.  
Subjects were secured into a chair and their leg secured to a force transducer (Dillion, Fairmont, 
MN) with a non-compliant strap.  Data was measured in volts and converted to force by a 
regression equation (Biopac AcqKnowledge, Goleta, CA).  Subjects were familiarized with the 
equipment by performing three warm up contractions (two submaximal, 1 maximal) separated by 
10 seconds of rest.  After the last maximal contraction subjects were instructed to rest for 5 
minutes followed by 3, 3 second maximum voluntary contractions of the quadriceps, interspersed 
with 10-second rest intervals between contractions with the highest peak torque from the 3 
contractions recorded.  Subjects were verbally encouraged during the maximal contractions.   
Range of motion 
Range of motion has been shown to be an accurate method of determining the extent of muscle 
damage (P. M. Clarkson, et al., 1992).  Subjects were instructed to lay prone on a massage table 
with both knees fully extended.  Subjects flexed their left knee with no help from the investigator 
and the angle measured with a goniometer (Prestige Medical, Northridge, CA) using universal 
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landmarks (lateral epicondyle of the femur, lateral malleolus and greater trochanter) that were 
marked to ensure consistency on subsequent measures.  Three measurements were averaged 
and reported in degrees.  This method has been validated previously (Watkins, Riddle, Lamb, & 
Personius, 1991). 
Thigh Girth 
Limb circumference has been proposed as a functional measure of muscle damage (Tiidus, 
2008).  Limb circumference was assessed from the midpoint of the greater trochanter and the 
lateral epicondyle of the dominant leg with an anthropometric tape (Idass, Glastonbury, UK).  
Subjects were standing fully relaxed in the anatomical position. Subjects were instructed to bear 
the majority of their weight on their dominant leg with three averaged measurements taken on 
their non dominant leg.  Measurement sites were marked to ensure consistency and 
measurements were reported in millimeters.  
Algometry  
Pressure algometry can be used to quantify muscle tenderness.  The validity and sensitivity of 
pressure algometry has been established in literature (Kosek, Ekholm, & Nordemar, 1993). 
Pressure was measured at five specific sites on the quadriceps with a digital algometer (Force 
One, Wagner Instruments, Greenwich, CT.).  The same investigator performed all measurements 
throughout the study.  Specific sites for assessment were determined using established literature 
and landmarks (Pumpa, et al., 2011) involving two anatomical points (anterior superior iliac spine 
(ASIS) and superior pole of the patella (SPP)).  All measurements were taken on the right side 
with the subject in the supine position. A longitudinal axis was created between the ASIS and the 
SPP from which the sites were marked with a permanent marker to ensure accuracy at each time 
point. The measured sites were: 15 cm distal to the ASIS, 4 cm proximal to the SPP, midpoint of 
the ASIS and SPP along the axis, then 2 cm lateral and 2 cm medial of this midpoint.  Subjects 
were instructed to let the investigator know when the pressure transformed into pain at which 
point the amount of force was recorded in newtons. 
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Muscle damaging exercise 
An established protocol was used to illicit muscle damage in trained athletes (Stephan Sorichter, 
et al., 1997) by downhill running on a treadmill (A.R. Young Company, Indianapolis, IN.) modified 
to run in reverse at a -16% gradient.   Before the test, 5 minutes of warm up preceded 20 minutes 
of running, followed by a 5 minute cool down period. Once the test commenced, subjects were 
not permitted to stop and treadmill speed was adjusted so the subject could maintain a heart rate 
that corresponded to 70% VO2 max. 
Blood assays  
Indirect markers of muscle damage were assayed for the following biomarkers.  Creatine kinase 
was measured by enzyme-linked immunoassay using a spectrophotometer at 450nm using a 
fluorometric assay kit (Abcam plc. Cambridge, England).  Myoglobin (Calbiotech Inc., Spring 
Valley, CA), troponin I, (Abnova, Taipei, Taiwan), Skeletal muscle troponin I, (USCN Life Science, 
Hubei PRC.), Fatty Acid Binding Protein 3 (GenWay Biotech Inc., San Diego, CA), Interleukin-6 
(Life Technologies Corporation, Grand Island, NY.), 8-OHdG (Cell Biolabs, San Diego, CA.) and 
TNF-alpha (Life Technologies Corporation, Grand Island, NY.).  An automated plate washer 
(Biotek ELx405, Winooski, VT) was used to wash the 96-well microplates during the pre-assay 
preparations. All assays were analyzed using a Powerwave XSTM Spectrophotometer.  The 
antibodies used in TNF-alpha, FABP3, Myoglobin, cTN1, IL-6, CK-MM, 8-OHdG, STN-I ELISA 
assays exhibited specificity with no detectable cross reactivity to any of the other intracellular 
constituents present in human serum.   Concentrations on all biomarkers were analyzed and 
reported. 
Data Analysis 
Data were analyzed using SPSS 21 (IBM, Armonk, New York) with statistical significance 
assessed at a level of p < 0.05. Data were analyzed with a repeated measures design.   
Normality was assessed with Shapiro-Wilks test and Levene’s test checked homogeneity of 
variance between groups.  Mauchly’s test was conducted to determine if sphericity was violated. 
If sphericity was violated, the ANOVA was corrected with a Greenhouse-Geisser adjustment 
factor.  A Fisher protected least-squares difference post-hoc test was used to detect differences 
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in group means (p < 0.05) where a significant F ratio was found.  Data are presented as mean 
plus or minus standard deviation with reliability presented as a 95% confidence interval.  
Sample size was determined using a post-hoc power analysis of existing literature using G*Power 
version 3.0.5 (Universität Kiel, Germany) (Faul, Erdfelder, Lang, & Buchner, 2007).  Effect sizes 
were presented as mean differences between groups divided by standard deviation.  Previous 
literature suggests that an experiment-wise error rate of 0.05 required at least 15 subjects within 
each treatment group (Fontani et al., 2005), (Guezennec, Nadaud, Satabin, Leger, & Lafargue, 
1989), (Santos, et al., 2012) (Tartibian, Maleki, & Abbasi, 2009), (Tartibian, Maleki, & Abbasi, 
2011).  In previous studies, ingestion of n-3 PUFA (n=9-15) for 30 days compared to 
placebo/control (n=9-15) significantly reduced inflammatory markers and perceived pain following 
eccentric exercise, with effect sizes ranging from 0.64-0.75 for a study power of 0.82 and 0.84 
respectively. Additionally, following 30 days n-3 PUFA supplementation (n=10), compared to 
placebo (n=10), a number of inflammatory markers were decreased directly after 5 days of 
military survival boot camp for effect sizes ranging from 0.61-0.75 for a study power of 0.84 
(Santos, et al., 2012). It is calculated that a sample size of 20 per group will provide a 96% power 
to detect differences in the series of proof of concept studies outlined in this proposal. Study 
power was maintained at 80% because fewer than five subjects withdrew or dropped from either 
side of the study (Adams et al., 1993). 
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Chapter 4: Results 
Subjects 
32 untrained males participated in the study (PCSO-524™: n=16, placebo: n=16) out of 40 that 
were recruited for the study. Mean age was 21.6 ± 2.0 years; mean height was 176.3 ± 6.6 cm 
and mean weight 70.8 ± 9.8 kg. All subjects exercised less than 3 times a week for 30 minutes a 
session.  Subject characteristics are summarized in Table 1 with no statistical difference between 
groups (p <.05). 
 
 Age  
(years) 
Height  
(cm) 
Weight  
(kg) 
Systolic BP 
(mmHg)  
Diastolic BP 
(mmHg) 
Glucose 
(mg/dL) 
Cholesterol 
(mg/dL) 
Placebo (n=16) 21.5 ± 
2.4 
174.2 ± 6.7 66.6 ± 9.7 123.6 ± 7.5 80.0 ± 6.7 85.4 ± 8.2 173.0 ± 12.0 
PCSO-524™ 
(n=16)  
21.7 ± 
1.7 
178.1 ± 5.8 74.8 ± 8.8 130.3 ± 11.0 82.2 ± 3.2 83.1 ± 9.2 166.4 ± 9.2 
P value 0.539 0.137 0.942 0.625 0.112 0.29 0.90 
Table 1: Subject parameters 
 
Maximal Voluntary Contraction 
The test of within-subjects effects indicates that there was a significant effect of time on force 
from baseline (F = 8.140 p < .001).  The lack of interaction between time and treatment suggests 
that this effect is consistent between placebo and PCSO-524™ groups (F = .851 p = .470).  
Finally the test of between-subjects effects indicates there is no significant effect of 
supplementation status on force from baseline (F = .163 p = .690).  Pairwise comparisons found 
that there was a statistically significant difference (p < 0.05) in the PCSO-524™ group at 96 hours 
after eccentric muscle damage compared to baseline (figure 5).  Additionally there was no 
difference in the baseline measures before or after supplementation (Table 2). 
 
 Treatment Mean (kg) Std. Deviation P value between 
groups 
Pre supplementation Placebo 75.4 19.3 .725 
 PCSO-524™  72.8 22.2  
Post supplementation Placebo 82.1  22.4 .988 
 PCSO-524™  82.2 19.7  
24 hours post downhill 
run 
Placebo 
74.9 19.4 
.861 
 PCSO-524™  76.2 19.8  
48 hours post downhill 
run 
Placebo 
74.6 22.5 
.596 
 PCSO-524™  78.7 21.5  
72 hours post downhill 
run 
Placebo 
76.2 20.8 
.608 
 PCSO-524™  79.9 20.2  
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96 hours post downhill 
run 
Placebo 
84.0 13.4 
.926 
 PCSO-524™  84.6 22.4  
Table 2 MVC force after various time points 
 
Figure 5: Maximal voluntary contraction measured in newtons. £ denotes significant 
difference (p < 0.05) from baseline (pre-supplementation) within groups. 
 
Range of motion 
The test of within-subjects effects indicates that there is a significant effect of time on range of 
motion (F = 4.105 p < .01), the lack of interaction between time and treatment suggests this effect 
is consistent between placebo and PCSO-524™ groups (F = 1.813  p = .114), finally the test of 
between-subjects effects indicates no effect of supplementation status on range of motion (F = 
.461 p = .502).  Pairwise comparisons found that there was a statistically significant difference in 
range of motion between groups 96 hours after the downhill run (F = 8.236  p < .05).  Additionally 
there was no difference in the baseline measures before or after supplementation (Table 3). 
 
 Treatment Mean Std. Deviation P value between 
groups 
Pre supplementation Placebo 45.75 8.37 0.505 
 PCSO-524™  47.50 6.13  
Post supplementation Placebo 46.88 9.78 0.946 
 PCSO-524™  46.69 5.03  
24 hours post downhill 
run 
Placebo 47.31 9.02 0.981 
 PCSO-524™  47.38 5.16  
48 hours post downhill 
run 
Placebo 43.44 7.11 0.611 
 PCSO-524™  44.63 5.92  
72 hours post downhill 
run 
Placebo 44.94 8.51 0.769 
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 PCSO-524™  45.69 5.44  
96 hours post downhill 
run 
Placebo 41.75 5.32 0.007 
 PCSO-524™  46.69 4.36  
Table 3: Range of Motion  
 
 
Figure 6: Range of motion vs. Time * denotes significance between placebo and PCSO-524 (p  < 
.05) 
 
Thigh girth 
The test of within-subjects effects indicates that there is no effect of time on percent change in 
muscle swelling from baseline (F = 1.061 p = .379), the lack of interaction between time and 
treatment suggests that this effect is consistent between Placebo and PCSO-524™ groups (F = 
.113  p = .978), finally the test of between-subjects effects indicates there is no difference 
between supplementation status on percent change in muscle swelling from baseline (F = .001 p 
= .997).  Pairwise comparisons found that there were no statistically significant percent changes 
from baseline thigh circumference between groups at any of the time points after the downhill run.  
Additionally there was no difference in the baseline measures before or after supplementation 
(Table 4). 
 
 Treatment Percent change 
from baseline 
Std. Deviation P value 
between 
groups 
Baseline  Placebo 0.0078 0.02376 0.631 
 PCSO-524™  0.0114 0.01808  
24 hours post muscle damage Placebo 0.0182 0.0263 0.970 
 PCSO-524™  0.0179 0.02225  
48 hours post muscle damage Placebo 0.0146 0.02073 0.953 
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 PCSO-524™  0.015 0.01918  
72 hours post muscle damage Placebo 0.0178 0.02332 0.582 
 PCSO-524™  0.0136 0.01865  
96 hours post muscle damage Placebo 0.0215 0.06243 0.971 
 PCSO-524™  0.0208 0.03755  
Table 4: Percent changes from baseline in thigh circumference 
 
Figure 7: Percent change from baseline thigh circumference  £ denotes significant 
difference (p < 0.05) from baseline (pre-supplementation) within groups. 
 
Algometry 
The test of within-subjects effects indicates that there is a significant effect of time on percent 
change from baseline in perception of pain by algometry (F = 3.287 p < .05), the lack of 
interaction between time and treatment suggests that this effect is consistent between Placebo 
and PCSO-524™ groups (F = .206  p = .935), finally the test of between-subjects effects 
indicates there is no effect of supplementation status on percent change from baseline in 
perception of pain by algometry (F = .025 p = .877).  Pairwise comparisons found that there were 
no statistically significant percent changes from baseline between groups at any of the time points 
after the downhill run.  Additionally, there was no difference in the baseline measures before or 
after supplementation (Table 5). 
 Treatment Mean deviation 
from baseline (%) 
Std. Deviation P-value between 
groups 
Baseline  Placebo -0.03 0.35 0.643 
 PCSO-
524™  
-0.08 0.32  
24 hours post muscle 
damage 
Placebo -0.15 0.27 0.844 
 PCSO-
524™  
-0.13 0.26  
48 hours post muscle 
damage 
Placebo -0.10 0.39 0.824 
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 PCSO-
524™  
-0.12 0.28  
72 hours post muscle 
damage 
Placebo -0.07 0.41 0.978 
 PCSO-
524™  
-0.07 0.34  
96 hours post muscle 
damage 
Placebo 0.01 0.50 0.896 
 PCSO-
524™  
-0.01 0.34  
Table 5: Percent change from baseline in perceived pain by algometry 
 
 
Figure 8: Percent change from baseline perceived pain by algometry. £ denotes significant 
difference (p < 0.05) from baseline (pre-supplementation) within groups. 
 
Creatine Kinase - MM 
The test of within-subjects effects indicates that there is a significant effect of time on creatine 
kinase in the blood (F = 346.132 p < .001), the interaction between time and treatment suggests 
that this effect is not consistent between Placebo and PCSO-524™ groups (F = 75.554 p < .001), 
finally the test of between-subjects effects indicates there is a significant effect of the 
supplementation on creatine kinase in the blood (F = 191.321 p < .001).   
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Figure 9: Creatine Kinase Appearance in Blood.  * denotes significant difference between 
groups (p  < .05); £ denotes significant difference (p < 0.05) from baseline (pre-
supplementation) within groups. 
 
Pairwise comparisons found there was a significant difference between groups immediately (t = 
4.467, p < .001; 95% CI = 63.0 – 169.2), 2 (t = 5.076, p < .001; 95% CI = 76.1 – 178.6), 24 (t = 
12.829, p < .001; 95% CI = 562.5 – 775.6), 48 (t = 11.477, p < .001; 95% CI = 493.2 – 706.7), 72 
(t =9.118, p < .001; 95% CI = 359.8 – 567.5), and 96 hours (t = 11.935, p < .001; 95% CI = 574.4 
– 811.6) post downhill run.  No significant difference was observed between groups pre 
supplementation and post supplementation after downhill running (Table 6). 
 Treatment Mean Std. Deviation P value between groups 
Before Supplementation Placebo 95.4 42.3 0.205 
 PCSO-524™  77.4 35.9  
After Supplementation Placebo 92.2 33.4 0.365 
 PCSO-524™  82.9 23.0  
0 hr post muscle damage Placebo 332.5 88.8 0.000 
 PCSO-524™  216.4 54.1  
2 hr post muscle damage Placebo 355.9 93.5 0.000 
 PCSO-524™  228.6 36.5  
24 hr post muscle damage Placebo 1055.2 175.2 0.000 
 PCSO-524™  386.1 113.3  
48 hr post muscle damage Placebo 1028.0 185.4 0.000 
 PCSO-524™  428.0 96.7  
72 hr post muscle damage Placebo 989.7 163.3 0.000 
 PCSO-524™  526.0 121.2  
96 hr post muscle damage Placebo 1189.8 213.1 0.000 
 PCSO-524™  496.8 92.4  
Table 6: Creatine Kinase-MM Appearance in Blood 
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Myoglobin 
The test of within-subjects effects indicates that there is a significant effect of time on myoglobin 
in the blood (F = 373.835 p < .001), the interaction between time and treatment suggests this 
effect is not consistent between Placebo and PCSO-524™ groups (F = 15.179 p < .001), finally 
the test of between-subjects effects indicates there is a significant effect of the supplementation 
on myoglobin in the blood (F = 34.229 p < .01).  Pairwise comparisons found there was a 
significant difference between groups at 24 (t = 4.334, p < .001; 95% CI = 22.9 – 63.7), 48 (t = 
6.402, p < .001; 95% CI = 67.7 – 131.1), 72 (t = 5.340, p < .001; 95% CI = 119.0 – 266.3), and 96 
hours (t = 3.272, p < .01; 95% CI = 49.0 – 212.3) post downhill run.  No significant difference was 
observed between groups pre supplementation, post supplementation, immediately and 2 hours 
after downhill running (Table 7). 
 
 
 Treatment Mean Std. Deviation P value between 
groups 
Before Supplementation Placebo 28.76 11.11 0.416 
 PCSO-524™  32.06 11.50  
After Supplementation Placebo 30.84 12.02 0.349 
 PCSO-524™  34.88 11.95  
0 hr post muscle damage Placebo 51.20 11.37 0.064 
 PCSO-524™  42.45 14.25  
2 hr post muscle damage Placebo 52.16 12.82 0.079 
 PCSO-524™  43.14 15.18  
24 hr post muscle damage Placebo 127.81 21.62 <.001 
 PCSO-524™  84.53 33.60  
48 hr post muscle damage Placebo 346.24 42.16 <.001 
 PCSO-524™  246.80 45.64  
72 hr post muscle damage Placebo 580.28 103.57 <.001 
 PCSO-524™  387.64 100.49  
96 hr post muscle damage Placebo 449.62 122.51 0.003 
 PCSO-524™  318.97 102.45  
Table 7: Myoglobin Appearance in Blood 
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Figure 10: Myoglobin Appearance in Blood.  * denotes significant difference between 
groups (p  < .05); £ denotes significant difference (p < 0.05) from baseline (pre-
supplementation) within groups. 
 
Troponin – I (Skeletal)  
The test of within-subjects effects indicates that there is a significant effect of time on skeletal 
muscle troponin I in the blood (F = 102.681 p < .001), the interaction between time and treatment 
suggests that this effect is not consistent between Placebo and PCSO-524™ groups (F = 7.397 p 
< .001), finally the test of between-subjects effects indicates there is a significant effect of 
supplementation on skeletal Muscle Troponin I in the blood (F = 10.265 p < .01).  Pairwise 
comparisons found that there was a significant difference between groups at 2 (t = 2.562, p < .05; 
95% CI = 0.9 – 8.0), 24 (t = 3.561, p < .01; 95% CI = 4.4 – 15.4), 48 (t = 4.095, p < .001; 95% CI 
= 4.7 – 14.0), 72 (T = 3.222, p < .01; 95% CI = 2.5 – 11.2), and 96 hours (T = 2.177, p < .05; 95% 
CI = 0.3 – 10.4) post downhill run.  No significant difference was observed between groups pre 
and post supplementation and immediately after downhill running (Table 8). 
 
 Treatment Mean Std. Deviation P value between 
groups 
Before Supplementation Placebo 8.36 3.06 0.544 
 PCSO-524™  7.67 3.33  
After Supplementation Placebo 7.77 3.47 0.618 
 PCSO-524™  7.12 3.82  
0 hr post muscle damage Placebo 13.24 4.51 0.109 
 PCSO-524™  10.68 4.25  
2 hr post muscle damage Placebo 17.93 5.56 0.016 
 PCSO-524™  13.48 4.16  
24 hr post muscle damage Placebo 30.21 9.03 0.001 
 PCSO-524™  20.33 5.98  
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48 hr post muscle damage Placebo 27.97 7.09 <.001 
 PCSO-524™  18.60 5.78  
72 hr post muscle damage Placebo 23.58 6.82 0.003 
 PCSO-524™  16.74 5.04  
96 hr post muscle damage Placebo 16.74 8.05 0.037 
 PCSO-524™  11.38 5.66  
Table 8 : Slow Skeletal Troponin I Appearance in Blood 
 
 
Figure 11: STN1 Appearance in Blood.  * denotes significant difference between groups (p  
< .05); £ denotes significant difference (p < 0.05) from baseline (pre-supplementation) 
within groups. 
 
Fatty acid binding protein 
The test of within-subjects effects indicates that there is a significant effect of time on fatty acid 
binding protein in the blood (F = 6.346 p < .001), the lack of interaction between time and 
treatment suggests that this effect is consistent between Placebo and PCSO-524™ groups (F = 
1.582 p = .142), finally the test of between-subjects effects indicates there is no effect of 
supplementation status on fatty acid binding protein appearance in the blood (F = .418 p = .523).  
Pairwise comparisons found that there was no significant difference between groups at any of the 
time points after a downhill.  Additionally there was no difference in the baseline measures before 
or after supplementation (Table 9). 
 
 Treatment Mean Std. Deviation P value between 
groups 
Before Supplementation Placebo 1873.0 1362.6 0.498 
 PCSO-524™  2266.6 1845.6  
After Supplementation Placebo 1860.6 1669.8 0.251 
 PCSO-524™  2654.9 2140.5  
0 hr post muscle damage Placebo 2451.7 2005.6 0.162 
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 PCSO-524™  3483.5 2063.0  
2 hr post muscle damage Placebo 3191.1 2146.6 0.546 
 PCSO-524™  3693.9 2497.0  
24 hr post muscle damage Placebo 2332.9 2767.8 0.287 
 PCSO-524™  3534.4 3458.8  
48 hr post muscle damage Placebo 1853.8 1987.2 0.97 
 PCSO-524™  1831.2 1336.1  
72 hr post muscle damage Placebo 1709.8 1460.4 0.582 
 PCSO-524™  1465.1 980.6  
96 hr post muscle damage Placebo 2306.2 3093.0 0.436 
 PCSO-524™  1620.2 1577.6  
Table 2: Fatty acid Binding Protein Appearance in Blood 
 
 
Figure 12: Fatty acid binding protein 3 appearance in blood.  £  denotes significant 
difference (p < 0.05) from baseline (pre-supplementation) within groups. 
Interleukin - 6 
The test of within-subjects effects indicates that there is a significant effect of time on interleukin-6 
concentration in the blood (F = 128.951 p < .001), the interaction between time and treatment 
suggests that this effect is not consistent between Placebo and PCSO-524™ groups (F = 8.722 p 
< .001), finally the test of between-subjects effects indicates there is a significant effect of 
supplementation status on interleukin-6 appearance in the blood (F = 9.930 p < .01).   
Pairwise comparisons found that there was a significant difference between groups at 24 (t = 
3.619, p < .01; 95% CI = 3.7 – 13.3), 48 (t = 3.993, p < .001; 95% CI = 5.8 – 17.8), 72 (t = 3.621, 
p < .01; 95% CI = 5.0 – 17.9), and 96 hours (t = 3.076, p < .01; 95% CI = 3.1 – 15.35) post 
downhill run.  No significant difference was observed between groups pre supplementation, post 
supplementation and immediately after downhill running (Table 10). 
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 Treatment Mean Std. Deviation P value between 
groups 
Before Supplementation Placebo 18.05 5.04 0.381 
 PCSO-524™  19.53 4.36  
After Supplementation Placebo 19.46 4.65 0.473 
 PCSO-524™  20.72 5.13  
0 hr post muscle damage Placebo 31.28 4.67 0.058 
 PCSO-524™  26.98 7.35  
2 hr post muscle damage Placebo 31.54 6.44 0.085 
 PCSO-524™  27.09 7.65  
24 hr post muscle damage Placebo 39.22 6.39 0.001 
 PCSO-524™  30.71 6.90  
48 hr post muscle damage Placebo 52.93 8.48 <.001 
 PCSO-524™  41.15 8.20  
72 hr post muscle damage Placebo 48.48 8.59 0.001 
 PCSO-524™  37.02 9.30  
96 hr post muscle damage Placebo 42.62 8.39 0.004 
 PCSO-524™  33.39 8.59  
Table 3: IL-6 Appearance in Blood 
 
Figure 13: IL-6 Appearance in Blood.  * denotes significant difference between groups (p  < 
.05); £  denotes significant difference (p < 0.05) from baseline (pre-supplementation) within 
groups. 
 
TNF - alpha 
The test of within-subjects effects indicates that there is a significant effect of time on TNF alpha 
concentration in the blood (F = 132.012 p < .001), the interaction between time and treatment 
suggests that this effect is not consistent between placebo and PCSO-524™ groups (F = 19.123 
p < .001), finally the test of between-subjects effects indicates there is a significant effect of 
supplementation status on TNF alpha appearance in the blood (F = 21.414 p < .001).   
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Figure 14: TNF-alpha Appearance in Blood.  * denotes significant difference between 
groups (p  < .05); £  denotes significant difference (p < 0.05) from baseline (pre-
supplementation) within groups. 
 
Pairwise comparisons found that there was a significant difference between groups at 24 (t = 
4.633, p < .001; 95% CI = 11.1 – 28.5), 48 (t = 4.942, p < .001; 95% CI = 10.6 – 25.7), 72 (t = 
4.747, p < .001; 95% CI = 11.3 – 28.5), and 96 hours (t = 6.349, p < .001; 95% CI = 16.8 – 32.8) 
post downhill run.  No significant difference was observed between groups pre supplementation, 
post supplementation, immediately, and 2 hours after downhill running (Table 11). 
 
 Treatment Mean Std. Deviation P value between groups 
Before Supplementation Placebo 25.68 6.71 0.406 
 PCSO-524™  23.80 5.88  
After Supplementation Placebo 23.53 5.94 0.688 
 PCSO-524™  24.37 5.72  
0 hr post muscle damage Placebo 29.42 6.51 0.579 
 PCSO-524™  28.17 6.10  
2 hr post muscle damage Placebo 38.94 8.07 0.086 
 PCSO-524™  33.99 7.67  
24 hr post muscle damage Placebo 65.81 14.77 <.001 
 PCSO-524™  46.01 8.60  
48 hr post muscle damage Placebo 62.95 11.82 <.001 
 PCSO-524™  44.80 8.73  
72 hr post muscle damage Placebo 62.17 14.04 <.001 
 PCSO-524™  42.27 9.17  
96 hr post muscle damage Placebo 61.29 13.06 <.001 
 PCSO-524™  36.48 8.59  
Table 11: TNF-alpha Appearance in Blood 
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8 - Hydroxyguanosine 
The test of within-subjects effects indicates that there is not a significant effect of time on 8-OHdG 
concentration in the blood (F = 1.018 p  .419), the lack of interaction between time and treatment 
suggests that this effect is consistent between placebo and PCSO-524™ groups (F = 1.005 p = 
.429), finally the test of between-subjects effects indicates there is no effect of supplementation 
status on 8-OHdG appearance in the blood (F = 3.250 p = .081).  Pairwise comparisons found 
that there was no significant difference between groups at any of the time points after the downhill 
run.  Additionally there was no difference in the baseline measures before or after 
supplementation (Table 12). 
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 Treatment Mean Std. Deviation P value between 
groups 
Before Supplementation Placebo 0.17 0.08 0.402 
 PCSO-524™  0.19 0.08  
After Supplementation Placebo 0.21 0.19 0.437 
 PCSO-524™  0.16 0.09  
0 hr post muscle damage Placebo 0.17 0.07 0.905 
 PCSO-524™  0.16 0.09  
2 hr post muscle damage Placebo 0.16 0.10 0.310 
 PCSO-524™  0.23 0.24  
24 hr post muscle damage Placebo 0.21 0.21 0.413 
 PCSO-524™  0.31 0.44  
48 hr post muscle damage Placebo 0.13 0.04 0.114 
 PCSO-524™  0.32 0.45  
72 hr post muscle damage Placebo 0.13 0.04 0.111 
 PCSO-524™  0.17 0.09  
96 hr post muscle damage Placebo 0.13 0.07 0.209 
 PCSO-524™  0.22 0.28  
 
Table 12: 8-OHdG Appearance in Blood 
 
Figure 15: 8-OHdG Appearance in Blood. No significant difference (p > 0.05) was observed 
between or within groups at any time point. 
 
Troponin – 1 (Cardiac) 
The test of within-subjects effects indicates that there is not a significant effect of time on cTn1 
concentration in the blood (F = .420 p = .889), the lack of interaction between time and treatment 
suggests that this effect is consistent between Placebo and PCSO-524™ groups (F = .381  p = 
.912), finally the test of between-subjects effects indicates there is no effect of supplementation 
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status on cTn1 appearance in the blood (F = 2.220 p = .148).  Pairwise comparisons found that 
there was no significant difference between groups at any of the time points after a downhill.  
Additionally there was no difference in the baseline measures before or after supplementation 
(Table 13). 
 Treatment Mean Std. Deviation P value between groups 
Before Supplementation Placebo 0.06 0.24 0.329 
 PCSO-524™  0.00 0.00  
After Supplementation Placebo 0.00 0.00 0.341 
 PCSO-524™  0.04 0.15  
0 hr post muscle damage Placebo 0.00 0.00 0.162 
 PCSO-524™  0.06 0.16  
2 hr post muscle damage Placebo 0.04 0.15 0.249 
 PCSO-524™  0.23 0.61  
24 hr post muscle damage Placebo 0.03 0.08 0.313 
 PCSO-524™  0.13 0.37  
48 hr post muscle damage Placebo 0.04 0.13 0.624 
 PCSO-524™  0.08 0.24  
72 hr post muscle damage Placebo 0.01 0.04 0.382 
 PCSO-524™  0.20 0.80  
96 hr post muscle damage Placebo 0.07 0.14 0.469 
 PCSO-524™  0.26 1.03  
Table 13: cTN1 Appearance in Blood 
 
Figure 16: cTn1 Appearance in Blood. No significant difference (p > 0.05) was observed 
between or within groups at any time point. 
 
Decisions on the Hypotheses 
1. PCSO-524™ supplementation attenuated force loss after muscle damage compared to 
placebo in untrained men at 96 hours post-eccentric exercise. The hypothesis that PCSO-524™ 
supplementation attenuates force loss after muscle damage following downhill running was 
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accepted. 
 
2. PCSO-524™ supplementation attenuated loss of range of motion compared to placebo in 
untrained men at 96 hours post-eccentric exercise. The hypothesis that PCSO-524™ attenuates 
loss of range of motion following downhill running was accepted. 
 
3. PCSO-524™ supplementation failed to lessen percent change in muscle swelling 
compared to placebo in untrained men following downhill running. The hypothesis that PCSO-
524™ supplementation attenuates percent change in muscle swelling following downhill running 
was not accepted. 
 
4. PCSO-524™ supplementation failed to lessen percent change from baseline in 
perception of pain by algometery compared to placebo in untrained men following downhill 
running. The hypothesis that PCSO-524™ supplementation attenuates percent change from 
baseline in perception of pain following downhill running was not accepted. 
 
5. PCSO-524™ supplementation attenuated appearance of creatine kinase compared to 
placebo in untrained men following downhill running. The hypothesis that PCSO-524™ 
attenuates the appearance of creatine kinase following downhill running was accepted. 
 
6. PCSO-524™ supplementation attenuated appearance of skeletal troponin I compared to 
placebo in untrained men following downhill running. The hypothesis that PCSO-524™ 
attenuates the appearance of slow skeletal troponin I following downhill running was accepted. 
 
7. PCSO-524™ supplementation did not attenuate appearance FABP in the blood 
compared to placebo in untrained men following downhill running. The hypothesis that PCSO-
524™ supplementation attenuates FABP in the blood following downhill running was not 
accepted. 
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8.  PCSO-524™ supplementation attenuated appearance of IL-6 compared to placebo in 
untrained men following downhill running. The hypothesis that PCSO-524™ attenuates the 
appearance of IL-6 following downhill running was accepted. 
 
9.  PCSO-524™ supplementation attenuated appearance of TNF-alpha compared to 
placebo in untrained men following downhill running. The hypothesis that PCSO-524™ 
attenuates the appearance of TNF-alpha following downhill running was accepted. 
 
10. PCSO-524™ supplementation failed to show any differences in 8-OHdG concentration 
compared to placebo in untrained men following downhill running. The hypothesis that PCSO-
524™ supplementation attenuates 8-OHdG concentration compared to placebo following downhill 
running was not accepted. 
 
11. PCSO-524™ supplementation failed to show any differences in the concentration of cTn1 
compared to placebo in untrained men following downhill running. The hypothesis that PCSO-
524™ supplementation attenuates appearances of cTn1 compared to placebo following downhill 
running was not accepted. 
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Chapter 5: Discussion 
  
The purpose of this study was to evaluate the effectiveness of PCSO-524™ in attenuating 
markers of EIMD/DOMS such as reduced muscle force, range of motion, muscle swelling, 
perceived muscle pain and the biochemical markers of muscle damage including CK-MM, 
Myoglobin, STN1, FABP3, IL-6, TNF-alpha, 8-OHdG, and cTN1.  PCSO-524™ supplementation 
can attenuate some of the biochemical markers of muscle damage and functional measures of 
muscle damage such as range of motion and maximal voluntary contraction; however 
supplementation with PCSO-524™ does not affect thigh girth and perceived pain through the use 
of algometry.  
Maximal Voluntary Contraction 
Strength loss after eccentric exercise is a common indicator of exercise induced muscle damage 
and has been used as a valid and reliable indirect marker of muscle damage after eccentric 
exercise in 50% of eccentric muscle damage studies in humans (Tiidus, 2008).  After eccentric 
muscle damage there can be up to a 50% loss in strength compared to baseline with restoration 
occurring up to 10 days after muscle damaging exercise.  Multiple hypotheses exist for the cause 
of force loss after eccentric exercise which include disruption of the myofilaments due to 
histological lesions as evidenced from muscle biopsies; attenuated neural activation patterns; and 
overstretched sarcomeres due to non uniform sarcomere length (P. M. Clarkson, et al., 1992). 
 
Force loss after eccentric muscle damage, measured by maximal voluntary contractions of the 
quadriceps, was significantly different between groups at 96 hours for the PCSO-524™ group 
compared to placebo suggesting PCSO-524™ supplementation has a protective effect on muscle 
damage during eccentric exercise by increasing force production post muscle damage.  These 
results are similar to Clarkson et. al. (1992) who investigated 2 bouts of high force eccentric 
exercise which resulted in substantial decreases in baseline force production immediately after 
eccentric exercise (P. M. Clarkson, et al., 1992).  
 
Supplementation of n-3 PUFAs, the principle ingredient in PCSO-524™, has been shown to 
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affect muscle strength by increasing grip strength in older adults (Robinson et al., 2008) by 
potentially increasing protein anabolism through the Akt-mTOR-S6K1 pathway (Gingras et al., 
2007a).  Additionally, n-3 PUFA supplementation has been shown to maintain muscle mass 
during muscle atrophy due to increases in amino acid delivery and anti-inflammatory action (P. C. 
Calder, 2009; Fujita, Rasmussen, Cadenas, Grady, & Volpi, 2006).  Another mechanism that n-3 
PUFAs may attenuate force loss during conditions of atrophy is through altered signaling 
pathways. Incorporation of n-3 PUFAs into the muscle phospholipid bilayer has been shown to 
increase PIP3 potency increasing phosphorylation of p70s6k, a crucial protein in the maintenance 
of muscle mass after resistance exercise (Alessi et al., 1997; Baar & Esser, 1999). 
 
The effect of PCSO-524™ supplementation on force production has been previously observed in 
Pumpa et. al. (2012) who investigated maximal voluntary contraction by counter movement and 
vertical jumping following downhill running and showed there was a non significant decrease in 
height and no significant difference between time points suggesting there was no affect for time 
or treatment in this study (Pumpa, et al., 2011).  Similarly, Kreider found that n-3 PUFA 
supplementation failed to promote strength gains in 23 experienced, resistance-trained subjects 
during a randomized double-blind study with either placebo (olive oil) or 6 grams/day of n-3 
PUFAs (conjugated linoleic acids) for 28 days. Despite a controlled training regimen there was no 
significant difference in strength compared to control (Kreider, Ferreira, Greenwood, Wilson, & 
Almada, 2002).  The lack of significant effects in both these studies may be explained by training 
status and supplementation period.    
  
The findings of Pumpa et. al. (2012) and Kreider et. al. (2002) may have been influenced by the 
use of trained subjects. Trained subjects have been shown to attenuate the clinical signs of 
muscle damage and decrease the amount of intracellular muscular proteins in the blood 
compared to untrained individuals (Appell, Soares, & Duarte, 1992; Ortenblad, Madsen, & 
Djurhuus, 1997).  The current study attempts to rectify this limitation by studying the effect of 
PCSO-524™ in untrained individuals whose muscles are less resilient to muscle damage (Tiidus, 
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2008).   
Range of Motion 
Inflammatory muscle swelling and myofibril disruption has been postulated to cause muscle 
stiffness and reduced range of motion.  Onset of reduced range of motion is gradual peaking 
around 3 days after eccentric muscle damage, and exhibits a similar time course to muscle 
swelling and therefore might be a result of reduced range of motion.  Clinical studies suggest that 
range of motion is decreased after post-traumatic edema and joint range of motion can be 
affected by muscle size which can vary between individuals (Airaksinen, Partanen, Kolari, & 
Soimakallio, 1991).  
 
Modification of the arachidonic acid pathway through the use of less inflammatory substrates 
such as n-3 PUFAs or the inhibition of eicosanoid synthesis by blocking COX enzymes has been 
shown in literature to attenuate inflammation, thereby increasing range of motion (Bjordal, 
Ljunggren, Klovning, & Slørdal, 2004; P. Calder & Grimble, 2002).   Kjeldsen-Kragh et. al (1992) 
found that subject consumption of  3.8 grams EPA /day and 2.0 grams of DHA /day for 16 weeks 
was effective at  decreasing morning stiffness despite a significant increase in morning stiffness 
in the placebo group (Kjeldsen-Kragh et al., 1992).  Further, Tartibian et. al. (2009) found 30 days 
of n-3 PUFA supplementation at 324 mg EPA /day and 216 mg DHA /day attenuated loss of 
range of motion compared to placebo 48 hours after eccentric exercise (B. Tartibian, et al., 2009).  
These data are in agreement with the present study, which found that while there was initially no 
significant difference between the placebo and PCSO-524™ groups immediately after eccentric 
exercise, range of motion increased over time with significant increases in the range of motion of 
the PCSO-524™ group 96 hours after muscle damaging exercise.  
 
Despite this theoretical basis of n-3 PUFA supplementation, there have been inconsistent results 
of eicosanoid pathway inhibition by the use of n-3 PUFA or NSAID supplementation on range of 
motion. Lenn and colleagues used 1.8 g/day n-3 PUFA with a 30 day supplementation period and 
failed to show a significant difference in relaxed arm angle after 50 maximal isokinetic eccentric 
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elbow flexion contractions at any time during the study (Lenn, et al., 2002).  Tokmakidis reported 
a similar effect with the use of NSAIDS (Tokmakidis, Kokkinidis, Smilios, & Douda, 2003).  Similar 
findings were observed by Barlas et. al. (2000) and Stone et. al. (2002) who showed no effect of 
eicosanoid inhibition on loss of ROM (Barlas et al., 2000; Stone, Merrick, Ingersoll, & Edwards, 
2002).   
 
The lack of significant findings in these studies differs from the present study that showed 
statistically significant differences in ROM 96 hours post eccentric exercise.  The lack of 
significant effects of n-3 PUFA supplementation in the studies conducted by (Lenn et. al. (2002), 
Barlas et. al. (2000), and Stone et. al. (2002) may be attributed to training status.  For example, 
Tartibian et. al. (2009) used untrained males and found 324 mg EPA and 216 mg DHA /day for 30 
days attenuated loss of range of motion and found the attenuation effect increased gradually post 
eccentric muscle damaging exercise with the first significant difference between placebo and n-3 
PUFA groups observed at the last time point measured in the study at 48 hours post eccentric 
muscle damaging exercise (B. Tartibian, et al., 2009). 
Thigh girth 
Swelling occurs within the muscle shortly after exercise and thigh circumference has been used 
as an indicator of exercise induced muscle damage caused by eccentric exercise due to muscle 
swelling and inflammation by influx of fluid into the muscle tissue (K. Nosaka & Newton, 2002). 
Swelling peaks 4 to 5 days post eccentric muscle damage with an initial increase in swelling 
occurring 0-1 hours post muscle damage in some studies. 
 
N-3 PUFA supplementation is hypothesized to attenuate inflammation by inhibiting the eicosanoid 
pathway since n-3 PUFAs are less inflammatory substrates than n-6 PUFAs and as a 
consequence, attenuate macrophage free radical production.  Diets rich in n-3 PUFAs found in 
the components in fish oil attenuate reactive oxygen species generation, production of 
inflammatory cytokines such as TNF-alpha, IL-1b and IL-6 by macrophages which lead to an 
attenuated response from the immune system (P. C. Calder, 1998).  Increased consumption of n-
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3 PUFAs such as EPA and DHA, result in the incorporation of n-3 PUFAs phospholipids in the 
membrane of the inflammatory cell at the expense of the more proinflamatory arachidonic acid. 
Because less substrate is available for synthesis of eicosanoids from arachidonic acid, fish oil 
supplementation decreases production of PGE2, thromboxane B2, LTB4, 5-
hydroxyeicosatetraenoic acid, and LTE4 by inflammatory cells (P. Calder & Grimble, 2002).  
Supplementation with n-3 PUFAs after eccentric exercise reduces muscle swelling 48 hours after 
exercise (Lenn, et al., 2002).   
 
However reduction in swelling by arachidonic acid pathway inhibition has not always been 
observed consistently in literature.  For example, there was no effect on arm circumference after 
eccentric arm exercises after supplementation of 2,000 mg EPA and 1,000 mg DHA per day 
(Jouris, McDaniel, & Weiss, 2011).  Similarly, Reynolds failed to demonstrate attenuation of thigh 
circumference following acute hamstring injuries by NSAID (300 mg/day) supplementation 
(Reynolds, Noakes, Schwellnus, Windt, & Bowerbank, 1995).  Reduction of inflammatory 
compounds has been demonstrated in a number of studies by supplementation of inhibitors such 
as n-3 PUFAs or NSAIDs suggesting that inhibition of eicosanoid production reduces swelling 
(Tiidus, 2008; Yang et al., 2010). 
 
One reason for the lack of observed difference in the present study might be that swelling was 
being affected by gravity.  Clarkson et. al. (1996) observed that the location of swelling in the 
muscle appears to change over time by using MRI and found that fluid began to accumulate in 
the lower portions of the extremities hypothesized to be due to the effects of gravity (Kazunori 
Nosaka & Clarkson, 1996).  The lack of significant time effects for both groups might be explained 
by examining other parts of the muscle for swelling rather than the midpoint.  In the present study 
the increase in TNF -α concentration is strongly linked to inflammation and it can be assumed 
muscle swelling might not be noticed since the effects of edema would be most noticeable in the 
distal end of the leg rather than the midpoint. 
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Some studies have found a poor correlation between the biochemical inflammatory markers and 
muscle swelling indicating that the two events might occur by two independent processes and 
suggests that the mechanism for muscle damage is not the underlying mechanism of exercise-
induced biomarker increase which would corroborate with the findings in the present study 
(Kazunori Nosaka & Clarkson, 1996; Sprenger et al., 1992).   
Algometry 
Delayed-onset muscle soreness is a hallmark manifestation of exercise-induced muscle damage 
a claim first made by Hough (1902).   Typically, DOMS develops between 24 and 48 hours after 
eccentric muscle damage and peaks within 72 hours postexercise (P. M. Clarkson, et al., 1992). 
The dull pain that signals DOMS is hypothesized to be caused by activation of afferent neurons 
by swelling and the subsequent pressure activates the mechanoreceptors. Another possible 
cause is the increased histamines, bradykinins, and prostaglandins produced by the inflammatory 
cells and breakdown of myocellular components that activate nociceptors that are sensitive to 
chemical signals (P. M. Clarkson, et al., 1992).  Algometry has been proposed as a reliable and 
effective way of quantifying pressure pain thresholds and muscle damage (Potter, McCarthy, & 
Oldham, 2006).  Further, algometry is a reliable measure and enhanced when being performed 
by one examiner and can be used to evaluate the development and decline of experimentally 
induced muscle tenderness over consecutive days (Nussbaum & Downes, 1998). 
 
Omega 3 fatty acids attenuate prostaglandin production and reduce inflammatory mediators by 
replacing arachidonic acid in the cell membrane.  After muscle damage, concentrations of 
calcium activated PLA2 increase, resulting in greater prostaglandin and leukotriene production. 
Additionally the antioxidants in PCSO-524™ such as furan fatty acids and vitamin E are powerful 
free radical scavengers, which minimize damage caused by NADPH oxidase in macrophages. 
DOMS has been attenuated by antioxidant supplementation such as Vitamin C and E (Bryer & 
Goldfarb, 2006).  PCSO-524™ supplementation has been beneficial in reducing perceived 
muscle soreness in athletes after a 30 kilometer run (Baum, et al., 2013).  Additionally, n-3 PUFA 
supplementation reduced the arachidonic/eicosapentaenoic acid ratio in the cell membrane and 
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the number of positive tender points in patients affected by musculoskeletal pain (Giuliano 
Fontani et al., 2010).    
 
The benefits of n-3 PUFA supplementation are well documented in literature for the prevention of 
muscle pain. Studies have found 1000 mg/day supplementation of EPA/DHA was enough to 
cause a increase in the tender point measured with algometry (Guimarães, Guimarães, & 
Raposo, 2011).  Additionally the n-3 PUFAs found in PCSO-524™ have been associated with 
decreased neuropathic pain with a study finding that between 2400-7200 mg/day of EPA and 
DHA was sufficient to attenuate the perception of pain by tender point algometry (Ko, Nowacki, 
Arseneau, Eitel, & Hum, 2010).   
 
These findings were corroborated with Pumpa et. al. (2012) who showed supplementation of the 
n-3 PUFA rich compound PCSO-524™ was ineffective at showing statistically significant 
differences in tender point algometry in trained athletes at the midpoint of the quadriceps 
following a downhill run.  This failure to find differences might have been the result of using 
trained athletes, since training confers a protective effect and as a consequence trained athletes 
are more resistant to muscle damage due to the repeated bout effect (Tiidus, 2008).   
 
The current study attempts to rectify the limitations in the Pumpa study by using untrained 
athletes whose muscles are more susceptible to the symptoms of EIMD/DOMS following downhill 
running.  The present study found that there was a significant effect for time, suggesting that 
muscle damaging exercise in the present study was effective at inducing muscle damage (F = 
3.287 p < .05) and the effect was effective for both the placebo and treatment groups (F = .206  p 
= .935).  However PCSO-524™ supplementation at the dosage and supplementation period was 
not effective in creating a significant difference between the control and placebo (F = .025 p = 
.877). These results assume that all participants were affected in the same way, however some 
participants claimed that their hamstrings, a muscle not measured, was more tender than their 
quadriceps.  Flexibility can determine which muscles are recruited and running gait can be 
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affected causing other muscle groups to compensate for weaker or stiffer muscles which can lead 
to damage (Hartig & Henderson, 1999).      
Creatine Kinase - MM 
Blood proteins such as creatine kinase have been proposed as indirect indicators of muscle 
damage and are routinely studied after strenuous exercise.  It is believed that after eccentric 
exercise the membrane of the muscle cell is damaged causing the release of creatine kinase, an 
enzyme that catalyzes phosphocreatine from creatine.  Creatine kinase is found and cells 
consuming ATP rapidly such as skeletal, and smooth muscle, photoreceptor cells of the retina 
and neurons in the brain.     
 
Due to multiple sources, increases in creatine kinase can be triggered by any number of events 
and increases have corresponded poorly with measures of EIMD/DOMS.  For example, an 
animal model, Kuipers et. al. (1985) reported that creatine kinase activity showed a poor 
correlation with a histological assessment of muscle damage (H. Kuipers, Keizer, Verstappen, & 
Costill, 1985).  Another study found that creatine kinase activity was much greater than actual 
tissue damage evaluated from tissue biopsy calculated by creatine kinase appearance and 
disappearance rates (Van der Meulen, et al., 1991).  An additional confounding problem is the 
large variability between subjects following the same exercise.  For example, Newham et. al. 
found that subjects who performed an eccentric exercise session had CPK activities ranging from 
500 U/L to 34,500 U/L creatine kinase with variability unrelated to general fitness level and 
physical characteristics of the subjects (Newham, Jones, & Edwards, 1983). 
A possible reason for these discrepancies is that creatine kinase is cleared by the mononuclear 
phagocyte system and any imbalance in production or clearance can lead to misestimating the 
effect of muscle damage after eccentric exercise.   
 
A novel first for this study was the use of an isoform of creatine kinase only found in skeletal 
muscle after downhill running.  The lack of significance of other studies in difference in creatine 
kinase after eccentric exercise may be to the use of the widely popular creatine kinase MB which 
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is found in multiple locations including muscles and the brain and can be released for multiple 
reasons other than muscle damage.  The isoform in this study utilized the isoform CK-MM that is 
the major isoform of creatine kinase expressed in skeletal muscle cells with other forms such as 
CK-MB playing a minor role (F. S. Apple, Rogers, & Ivy, 1986).  Other studies have confirmed the 
efficacy of CK-MM as a reliable indicator of muscle damage in both athletes and diseased 
individuals (F. Apple, et al., 1988; Page, Jackson, Coakley, & Edwards, 1989). 
 
The present study has shown that PCSO-524™ can significantly attenuate CK-MM levels 
compared to placebo following downhill running (F = 191.321 p < .001).  Significant differences 
were observed immediately, 24, 48, 72, and 96 hours after the downhill run (p < .05) with 
maximal values observed at 72 hours and 96 hours for the PCSO-524™ and placebo groups 
respectively which is in agreement with previously published literature which suggests creatine 
kinase increases 24 hours after muscle damaging exercise and peaks within 3-5 days (Tiidus, 
2008).   
 
The results in the present study differ from the Pumpa et. al. (2012) study which failed to show a 
significant difference in creatine kinase concentrations for trained athletes supplemented with 
PCSO-524™ compared to placebo after a downhill run.  One explanation for the failure to show 
significance may be due to the creatine kinase isoform in the study was specific to both muscle 
and brain and not just skeletal muscle as in the present study.  Another reason for the differences 
observed between studies may be due to a greater supplementation of PCSO-524™ per day, 
(200 mg PCSO-524™/day) in the Pumpa study in comparison to the present study (400 mg 
PCSO-524™/day). 
Myoglobin 
Myoglobin is a heme protein of striated muscle and is rapidly released after muscle damage. 
Myoglobin is involved in oxygen binding, storage and diffusion in cardiac and skeletal muscle 
fibers. It accounts for up to 5 to 10% of all cytoplasmic proteins with the highest concentration 
located close to the contractile apparatus and the intracellular membranous or fibular structures. 
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Since myoglobin is only found in skeletal muscle cells, it’s appearance in the blood is 
hypothesized to be due to ruptured cell membranes following eccentric muscle action and the 
amount of protein released into the blood is correlated with the magnitude of muscle damage 
(Van Nieuwenhoven et al., 1995).  In skeletal muscle, myoglobin is found mainly in slow-twitch 
fibers with current myoglobin assays unable to discriminate between myoglobin released from the 
heart or from skeletal muscle, and therefore myoglobin is not muscle specific (Delanghe, 
Chapelle, & Vanderschueren, 1990). Use of myoglobin has been problematic since production 
has not always been correlated with actual muscle damage.  Some studies have correlated 
myoglobin with muscle damage through verification with muscle biopsy (Dawson et al., 2002) and 
through disruption of the muscle membrane (Driessen-Kletter, Amelink, Bär, & Van Gijn, 1990). 
 
Supplementation of n-3 PUFAs has been used to attenuate the effects of muscle damage on 
myoglobin appearance in the blood (Tartibian, Maleki, & Abbasi, 2011).  The effect observed was 
similar to the present study with the appearance of myoglobin in the blood increasing until 48 
hours after eccentric muscle damaging exercise with levels in the study of myoglobin for control 
(393.4 +/- 133.2) and treatment 200.1 +/- 120.4) not statistically different than control (346.2 +/- 
42.2) and treatment (246.8 +/- 45.6) in the present study at 48 hours post muscle damaging 
exercise.  Additionally, the study findings are in agreement with other studies that have found 
elevated myoglobin levels 24 to 96 hours post eccentric muscle damage (Tiidus, 2008).  The 
findings of the present study agree with previous studies that show that n-3 PUFA 
supplementation has been effective in attenuating muscle damage post eccentric muscle 
exercise (Lenn, et al., 2002).  
 
The findings in the present study that PCSO-524™ significantly decreased myoglobin release 
following exercise induced muscle damage is in disagreement with Pumpa (2012) who found no 
difference between treatment and placebo groups of trained athletes during downhill running with 
supplementation of 200 mg PCSO-524™/day at any time point in the study (Pumpa, et al., 2011).  
The maximal values for myoglobin concentration were much earlier than the present study (6 
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hours versus 72 hours) after muscle damaging exercise might be attributed to excessive 
myoglobin clearance by the kidney.  Ritter et al (1979) found that myoglobin clearance is altered 
after exercise training with significant increases in clearance and decreases in total myoglobin 
plasma concentration in 16 male subjects following strenuous physical evaluation tests.  The 
present study attempts to rectify this deficiency by using untrained individuals which are more 
susceptible to EIMD/DOMS (Ritter, Stone, & Willerson, 1979).   
 
Another explanation for the discrepancy between the present study and the study conducted by 
Pumpa et al (2012) may be explained by the muscle damaging protocol used in the Pumpa study 
was not severe enough to illicit muscle damage in trained athletes.  Since trained subjects 
experience the repeated bout effect, which protects against subsequent muscle damage, the 
magnitude of damage is important in eliciting EIMD/DOMS.  The current study utilizes a protocol 
that has been shown to illicit muscle damage in trained individuals by using a greater slope (-16% 
vs. -10%) and longer duration of exercise (20 minutes continuous) in contrast to the study 
conducted by Pumpa and colleagues.  The protocol was successful in inducing muscle damage 
and myoglobin release as evidenced by a significant treatment effect for time (F = 373.835 p < 
.001). 
Troponin – I (Skeletal) 
Skeletal troponin I (sTnI) has been proposed as an alternative to commonly used muscle damage 
markers such as creatine kinase and myoglobin (Sorichter et al., 1997).  Current biomarkers such 
as creatine kinase are highly variable both within subjects and between subjects making them a 
poor estimator of exercise induced muscle damage.  Both creatine kinase and myoglobin are 
actively cleared from the blood by the reticuloendothelial system and myoglobin through the 
kidney, and alterations in the rates of clearance and production can lead to differences in the 
blood that do not accurately reflect the extent of muscle damage (Tiidus, 2008).  Skeletal muscle 
troponin I is located on the force-producing units of the sarcomere, which is responsible for 
binding with calcium causing tropomyosin to shift revealing the myosin binding sites which are 
responsible for force production.  Since this protein is unique to skeletal muscle cells, any 
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appearance in the blood is believed to be indicative of muscle damage (S Sorichter, Puschendorf, 
& Mair, 1999).  The cardiac isoform of STN1 has been used as a reliable diagnostic marker for 
patients suffering from heart attack.  Due to the unique specificity to skeletal muscle sTnI has 
been suggested as a possible gold standard of measuring the extent of muscle damage (Stephan 
Sorichter, et al., 1997). 
 
The current study is novel in that it is the first to measure the appearance of STN1 in the blood 
after muscle damaging exercise. The results of the study found that the downhill run at -16% for 
20 minutes was sufficient to induce elevation of sTnI serum levels with the placebo group 
experiencing statistically elevated levels of sTN1 compared to the PCSO-524™ group. 
Differences in sTnI levels were observed at 2, 24, 48, 72 and 96 hours after eccentric muscle 
damaging exercise. Levels of sTnI were greatest 24 hours after eccentric muscle damage and 
(PCSO-524™: 20.3 ± 6.0 ng/ml, placebo: 30.2 ± 9.0 ng/ml) differ slightly from a study conducted 
by Sorichter et. al. (1997) who found that maximal values occurred 6 hours after muscle 
damaging exercise.  This difference might be explained since the study used trained athletes 
rather than the current study that used untrained subjects who are subject to the repeated bout 
effect.  While the maximal values of stN1 are similar it is entirely possible that the subjects in the 
current study experienced much higher concentrations than measured at 24 hours since blood 
was not taken 6 hours after exercise. The data from the present study indicates the downhill 
running eccentric exercise protocol was successful in inducing muscle damage as evidence by 
appearance in the blood. 
 
There are differences among reported sTnI levels in the literature that maximal values in trained 
individuals appear 6 hours post exercise and can be influenced by gender and mode of exercise. 
For example after a downhill run Sorichter (2001) noted that median values for females were 
much lower than for males (8.2 mg/ L; M: 22.0 mg/L) (S Sorichter et al., 2001).  The resting 
baseline values of stn1 are similar to those in literature 8.7 ± 3.0 sTnI which are similar to 
Soricther et. al. (1999).  Additionally mode of exercise showed differing amounts of STN1 release 
 80 
with knee extensor exercises having a 4 fold increase compared to downhill running and it is not 
understood as to the reason for the increase between the two modes of exercise (D. S. 
Willoughby, VanEnk, & Taylor, 2003). 
Fatty acid Binding Protein 
An adequate supply of long-chain fatty acids for metabolism by skeletal muscle is important as 
fatty acids are important building blocks for membrane phospholipids which are the main 
substrate for energy production, especially in slow-twitch oxidative muscle fibers and serve as 
signaling molecules for inflammatory processes such as arachidonic acid (Van Nieuwenhoven et 
al., 1995).  During times of cellular stress, concentrations of these molecules are elevated to 
maintain homeostasis.  FABP3 can serve as the cytosolic equivalent of albumin in plasma by 
carrying fatty acids thereby increasing the overall rate of utilization inside the cell and transfer of 
fatty acids from the intracellular membrane (Weisiger, 2002).  While there are many different 
isoforms of fatty acid binding protein, FABP3 has been proposed as an isoform for reliably 
monitoring skeletal muscle damage due to a high concentration in skeletal muscle tissue.  FABP3 
expression in skeletal muscle is altered in response to physiological stimuli such as endurance 
training and in certain pathophysiological conditions, such as metabolic situations, which increase 
fatty acid oxidation and result in elevated FABP3 concentrations (Pritt, et al., 2008; Storch & 
Thumser, 2000). Damaged muscle cell membranes leak FABP3 into the interstitial space and 
capillaries. FABP3 has been shown to be a reliable and early diagnostic indirect marker of 
skeletal muscle damage (Pritt, et al., 2008).  Additionally, Fabp3 had greater diagnostic value 
than when combined with other markers of muscle damage such as creatine kinase-MM (Pritt, et 
al., 2008). 
 
The present study is novel in that it assesses the effectiveness of PCSO-524™ supplementation 
on attenuation of muscle damage which was evaluated by FABP3 after exercise induced muscle 
damage in humans.  The present study found that there was a significant effect for time and 
appearance of FAB3 in the blood (F = 6.346 p < .001) suggesting that muscle damage had 
occurred and the effect was consistent in both groups (F = 1.582 p = .142).  While no statistical 
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significant differences were observed between control and placebo, maximal values occurred two 
hours after eccentric muscle damage.  Pairwise comparisons revealed that there was significant 
increases immediately after downhill running in both groups and these results are consistent with 
literature suggesting that increases in plasma concentrations occur 1-24 hours post muscle 
damage (Schmitt et al., 2003).  However there was no difference between groups when 
comparing PCSO-524™ to placebo groups.  This may suggest that the constituents in PCSO-
524™ were unable to control lipid peroxidation compared to control.  The lack of observed 
difference between control and PCSO-524™ groups might have been due to increased rates of 
fatty acid metabolism during exercise that can affect availability and appearance in blood.  Other 
studies have paired fatty acid binding protein with other biomarkers such aspartate 
aminotransferase to improve diagnostic value (Pritt, et al., 2008).  
Interleukin - 6 
Interleukin-6 is produced in response to working skeletal muscle and intensity and exercise 
duration can affect IL-6 release. Muscle-derived IL-6 is responsible for glucose homeostasis by 
exerting an effect on adipose tissue and the liver during exercise and mediating exercise induced 
lipolysis. Muscle-derived IL-6 also inhibits pro-inflammatory cytokines such as tumor TNF-alpha 
that is produced by adipose tissue and inflammatory cells and plays a role in pathogenicity in 
diabetes and coronary artery disease. 
 
IL-6 can have many sources, including production by immune cells and the skeletal muscle itself.  
IL-6 stimulates the immune system and is produced by T cells and macrophages during infection 
and after trauma leading to inflammation (van der Poll et al., 1997). Additionally it has been 
shown that IL-6 is produced by the muscle with evidence supporting levels of other biomarkers 
such as creatine kinase and myoglobin were poorly correlated to IL-6 appearance in the blood (B. 
K. Pedersen, Steensberg, & Schjerling, 2001). It has been proposed that the large and immediate 
increase in IL-6 concentration in the blood in response to exhaustive exercise is independent of 
muscle damage, while muscle damage itself is followed by repair mechanisms which include 
invasion of macrophages which trigger a smaller magnitude of IL-6 release which is followed by a 
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second and much larger wave of IL-6 release related to muscle contractions (B. K. Pedersen, et 
al., 2001). Studies have found that antioxidant treatment with vitamin C and vitamin E, failed to 
attenuate muscle damage and suggests IL-6 is not related to muscle damage and may be a 
hormone action used in homeostatic maintenance of injured myofibrils (Petersen et al., 2001). 
Other studies have found that exercise-induced destruction of skeletal muscle fibers may trigger 
local production of IL-6 after prolonged running (Ostrowski, Rohde, Zacho, Asp, & Pedersen, 
1998).  
 
Supplementation with n-3 PUFAs protects muscle cell membrane integrity and attenuates 
inflammation by inhibiting the arachidonic acid pathway in macrophages (Machado et al., 2012). 
In the present study supplementation of PCSO-524™ attenuated IL-6 compared to placebo.  This 
suggests that the muscle damaging exercise was successful in disturbing IL-6 levels from 
baseline.  Current literature suggests that peak values for IL-6 occur between 8 and 72 hours 
post exercise, concurrent with this study which found significant increases in IL-6 concentrations 
from baseline detected between 24 and 48 hours for both placebo and treatment groups 
(Bruunsgaard et al., 1997; Phillips, Childs, Dreon, Phinney, & Leeuwenburgh, 2003).  Other 
studies have found significant effects between 4 and 6 hours but no difference at 24 hours and 
beyond.  However the protocols of muscle damage were not as robust as the one employed in 
this study with more severe bouts of eccentric muscle damage leading to larger and delayed IL-6 
release (Febbraio & Pedersen, 2002; Steensberg et al., 2002; D. Willoughby, McFarlin, & Bois, 
2003).  PCSO-524™ reduced the appearance of IL-6 compared to placebo, with the majority of 
IL-6 production occurring in muscle rather than monocytes (Febbraio & Pedersen, 2002).  This 
protective effect may be due to PCSO-524™ forming several potent anti-inflammatory lipid 
mediators such as resolvins and protectins which together suppress the activity of nuclear 
transcription factors, such as NF-κB, and reduce pro-inflammatory enzymes and cytokine 
production (Kang & Weylandt, 2008).   
 
These findings were contradicted by Pumpa et. al. (2012) who found no difference between 
 83 
placebo and treatment groups and appearance of IL-6 in plasma.  It appears that training status 
affects the appearance of IL-6 with trained athletes showing a much lower training response than 
untrained subjects (Fischer, 2006).  Additionally, the source of the IL-6 increase must be 
questioned as the maximal increase in the present study is 20 times greater than the Pumpa 
study (52.9 pg/ml +/- 8.5 pg/ml;  placebo 41.2 pg/ml +/- 8.2 pg/ml PCSO-524™).  Additionally the 
maximal value in the present study occurred much later (48 hours) than the Pumpa study 
(immediately after exercise).  This suggests that IL-6 production in the present study was induced 
by the damaged muscle as the findings correlate with other studies regarding magnitude and 
timing of IL-6 production after eccentric exercise (Ostrowski, et al., 1998). 
TNF - alpha 
Measurement of TNF-α following post eccentric muscle damage has been used as an indirect 
measurement of muscle damage.  Measurement of TNF-αprovides a quantitative measure of 
early phases of atherosclerosis and inflammation (Tiidus, 2008). 
 
Supplementation of n-3 PUFAs has been shown to decrease expression of TNF-alpha and 
reduce the proinflammatory effects associated with muscle damage (Lenn, et al., 2002) however 
the mechanism for attenuation remains unclear.  Additionally, n-3 PUFA and PUFA analogs 
decrease TNF-α secretion by RAW 264.7 macrophages.  Activated macrophages induce 
transcription of COX2 genes causing prostaglandin synthesis and inflammation (Wadleigh, 
Reddy, Kopp, Ghosh, & Herschman, 2000).   It is postulated that increases in the n-3 PUFA 
content of the macrophage membrane decrease the excitability of the macrophages attenuating 
the immune response by modulating eicosanoid signaling (Norris & Dennis, 2012).  Alternatively, 
the antioxidants in PCSO-524™ such as vitamin E and furan fatty acids minimize the formation of 
reactive oxygen species attenuating lipid peroxides and as a consequence tissue damage 
(Reznick, et al., 1998). 
 
TNF-α was significantly increased following eccentric muscle damage in the present study with 
the PCSO-524™ group experiencing a greater attenuation in TNF-α production compared to 
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placebo.  The placebo group experienced a maximal increase in TNF-α 24 hours after eccentric 
muscle damaging exercise (65.80 +/- 14.8) compared to PCSO-524™ (46.0 +/- 8.6).  While there 
were no differences at baseline every point after eccentric muscle damage was greater for the 
control compared to PCSO-524™ which suggests that PCSO-524™ supplementation has a 
protective effect by attenuating the immune response as evidenced by a decrease in TNF-α 
production. 
 
The levels of TNF-α observed in the present study are significantly higher than levels of TNF-α 
observed in other exercise studies.  Signorello et al (2003) observed baseline values in rested 
subjects before exercise of 9.32 ng/dl +/- 2.35 ng/dl and after 5 minutes of treadmill running was 
11.5 ng/dl +/- 2.45 ng/dl (Santo Signorelli et al., 2003).  Similarly Pumpa et al (2012) obtained 
values between 7 and 9 pg/ml which are significantly lower than the present study.  This 
discrepancy may be due to the use of trained individuals, which attenuates TNF-α release with 
lower levels observed in higher trained athletes (Kvernmo, Olsen, & Osterud, 1992).  Additionally, 
the time course data in the present study suggests that muscle damage occurred since there was 
greater than a 60% increase in TNF-α concentration within the first 24 hours, which can be 
correlated to other markers of muscle damage (Mackinnon, 1999).  This effect was not observed 
in the Pumpa study with the concentration of TNF-α peaking immediately post exercise 
suggesting that the eccentric exercise was not severe enough.  To overcome these obstacles, the 
present study used a much steeper incline that has been shown to induce muscle damage.  
Second, the use of untrained subjects in the present study helped maximize the treatment effect 
of downhill running since trained runners muscles are more difficult to damage due to the 
repeated bout effect (McHugh, 2003). 
8 - Hydroxyguanosine 
Both DNA damage and inflammation have been observed after exhaustive exercise suggesting 
that exercise-induced DNA damage might either be a consequence of inflammatory processes or 
involved in inflammation and immunological alterations after strenuous prolonged exercise.  It 
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appears that reactive oxygen species appear to be effectors which link inflammation with DNA 
damage.  
 
DNA damage has been shown to be present after endurance events lasting over 4 hours such as 
ultramarathons and marathons (Umegaki, Daohua, Sugisawa, Kimura, & Higuchi, 2000) (Gomez-
Cabrera et al., 2006) (Gomez-Cabrera, et al., 2006; Mastaloudis, et al., 2004).  Studies 
investigating DNA damage after short duration submaximal and maximal tests in the laboratory 
have shown no DNA damage (Neubauer, Reichhold, Nersesyan, Konig, & Wagner, 2008).  For 
example, DNA damage was not observed after intense treadmill running in either moderately or 
well trained athletes (Peters, Van Eden, Tyler, Ramautar, & Chuturgoon, 2006; K Umegaki, 
Higuchi, Inoue, & Esashi, 1998).  Further Sato et al. (2003) showed that moderate exercise does 
not result in DNA damage measured by 8-OHdG (Sato, Nanri, Ohta, Kasai, & Ikeda, 2003). 
Researchers using a similar method of inducing muscle damage in the present study using 
eccentric exercise by downhill running at -16% for 45 minutes found that while subjects 
experienced similar increases in serum biomarkers indicative of muscle damage 8-OHdG serum 
levels were unaffected by exercise (Sacheck, Milbury, Cannon, Roubenoff, & Blumberg, 2003).  
The lack of damage associated with exercise depends on the balanced between oxidant 
producing mechanisms such as increases in aerobic metabolism and the rate of free radical 
removal by antioxidant systems (Jacob & Burri, 1996).  In exercise lasting up to 40 minutes 
consumption of antioxidant levels in a typical athlete’s diet provides sufficient protection against 
the effects of free radical production without additional supplementation of antioxidants or n-3 
PUFAs.  Therefore, we can assume in the present study subjects were properly protected from 
DNA damage by their current diets (Watson et al., 2005). 
 
The lack of change in 8-OHdG post muscle damaging exercise in the current study is consistent 
with literature finding no significant changes in DNA damage after short bouts of exercise.  There 
was not a significant effect of time on 8-OHdG concentration in the blood (F = 1.018 p  .419), the 
lack of interaction between time and treatment suggests that this effect is consistent between 
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placebo and PCSO-524™ groups (F = 1.005 p = .429).  Finally the test of between-subjects 
effects indicates there is no significant effect of supplementation status on 8-OHdG appearance 
in the blood (F = 3.250 p = .081) which suggests the supplement had no effect on DNA damage 
after exercise.  
Troponin – 1 (Cardiac) 
Heart troponins such as cTn1 are used as specific markers to detect damage to myocardial 
tissue.  Since creatine kinase, fatty acid binding protein and myoglobin are also found in cardiac 
muscle they have been used as indicators of muscle damage following myocardial infarction.  In 
order to rule out cardiac tissue as a source of these proteins in the current study, there must be 
no significant increase following muscle-damaging exercise otherwise any increase in these 
proteins cannot be attributed to skeletal muscle alone.   
 
In the present study, there was no significant effect of time on cTn1 concentration in the blood (F 
= .420 p = .889).  Additionally the lack of interaction between time and treatment suggests that 
this effect is consistent between placebo and PCSO-524™ groups (F = .381  p = .912), finally the 
test of between-subjects effects indicates there is no effect of supplementation status on cTn1 
appearance in the blood (F = 2.220 p = .148).  Established literature suggests that cardiac muscle 
damage occurs when levels of cTN1 are above 10 μm/L (Hedström et al., 2007).  Since all 
values for all subjects are under this level for all time points, it can be assumed any increases in 
muscle intracellular proteins can be attributed to disruption of skeletal muscle fibers and not 
cardiac muscle.  
Future directions  
The present study demonstrated that supplementation of PCSO-524™ attenuated the 
appearance in blood of TNF-alpha, STN1, Myoglobin, CK-MM, and IL-6 and attenuated loss of 
range of motion and enhanced maximal voluntary contraction post muscle damaging exercise.  
Further research could look into inducing muscle damage to a greater extent by having subjects 
run at a steeper grade or run for a longer duration. Additionally, it might be helpful to look at the 
protective effect that PCSO-524™ can play in strength training rather than endurance training.  
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Conclusion 
In conclusion, the present study has shown that a lipid extract known as PCSO-524™ attenuates 
skeletal muscle damage in untrained men as measured by indirect biochemical measures of 
muscle damage such as sTN1, CK-MM, TNF-alpha and myoglobin, range of motion and 
enhanced maximal force production from baseline.  This study supports data from other studies 
(Tartiban et. al (2009) and Bloomer et. al (2009) that chronic n-3 PUFA supplementation provides 
a protective effect against EIMD following eccentric exercise in untrained males (R. J. Bloomer, 
D. E. Larson, K. H. Fisher-Wellman, A. J. Galpin, & B. K. Schilling, 2009; B. Tartibian, et al., 
2009). 
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